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1 Abstract 
Ageing of the immune system, also called immunosenescence, is a phenomenon that leads to 
increased susceptibility to infections in elderly people. Persistent cytomegalovirus (CMV) 
infection induces strong T cell responses in humans and is thought to be one of the driving 
forces of immunosenescence.  
In this work CMV-induced alterations in the T cell compartment of human individuals were 
analysed in terms of frequencies and absolute numbers per ml blood. Peripheral blood 
mononuclear cells (PBMC) from 50 donors in three different age groups were stimulated in 
vitro and examined for the phenotypic markers CD45RA and CD27 and the effector molecules 
CD40L, IFNγ, IL2 and TNF by polychromatic flow cytometry. For this purpose, an 11-colour 
flow cytometric panel was established.  
The results showed that the memory T cell subset distribution became further differentiated 
with advancing age of the donor. Further differentiated T cells expressed less CD3, CD4 and 
CD8 on their surface than TN cells.  
The frequency of responding polyfunctional T cells to stimulation with OKT3 or CMV peptide 
pools phosphoprotein 65 (pp65) or immediate-early protein1 (IE1) increased with the age of 
the donor. The memory subset distribution differed between CMV-seronegative and CMV-
seropositive donors and was correlated with the response size in the CMV-seropositive group. 
CMV infection with large CMV-specific T cell responses resulted in further differentiated T 
cell subsets.  
In addition, CMV infection appeared to affect unrelated immune responses. The results 
showed that CMV-infected donors had higher numbers of activated T cells following 
stimulation with OKT3 or purified protein derivate (PPD) from Mycobacterium tuberculosis. 
Although the cytokine profile of responding T cells appeared to be very similar in CMV-
negative and CMV-positive individuals, CMV-infected donors had more highly differentiated 
T cells.  
Polyfunctional T cells expressed quantitatively and qualitatively more activation marker on a 
per cell level than monofunctional cells and therefore appeared to be more effective. 
Abstract  6 
Furthermore, polyfunctional T cells expressed reduced amounts of surface CD3, CD4 and CD8 
compared to monofunctional or non-responding T cells.  
To examine the effect of the immunosuppressive drugs cyclosporine A (CSA) and tacrolimus 
(FK506) on CMV-specific T cells, the activation molecules CD40L, IFNγ, IL2, TNF and 
CD107a were analysed. In vitro incubation of PBMC with CSA and FK506 did not alter the 
frequency of T cells responding to pp65 but inhibited the expression of CD40L, IFNγ, IL2 and 
TNF. Degranulation of pp65-specific T cells was not affected. 
In summary, the results indicate that CMV has a significant influence on the immune system of 
healthy people. The memory subset composition of the entire T cell compartment depends on 
how the immune system responds to CMV (large or small responses) rather than the presence 
or absence of infection. Irrespectively of response size or age a robust population of 
polyfunctional CMV-specific T cells is present and may be in control of CMV. 
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2 Zusammenfassung 
Die Veraenderungen des Immunsystems mit zunehmendem Alter, auch Immunseneszenz 
genannt, resultieren in erhoehter Infektanfaelligkeit. Infolge dessen leiden aeltere Menschen 
unter haeufigeren und schwerer verlaufenden Infekten, Autoimmunerkrankungen und 
vermindertem Impfschutz. Immunseneszenz entsteht nicht nur aufgrund chronologischen 
Alterns, sondern wird auch durch andere teils ungeklaerte Faktoren verursacht. Cytomegalievirus 
(CMV) ist ein Herpesvirus, dass nach primaerer Infektion in immunkompetenten Menschen 
lebenslang persistiert. Infolge chronischer Immunaktivierung traegt CMV zur beschleunigten 
Immunseneszenz bei.  
In dieser Arbeit wurden die Alters- und CMV-induzierten Veraenderungen in humanen T-Zellen  
analysiert. Dafuer wurden PBMC von 50 gesunden Spendern in drei verschiedenen 
Altersgruppen antigenspezifisch (CMV-Proteine pp65 und IE1 und protein purified derivate von 
Mycobacterium tuberculosis (PPD)) und polyklonal (OKT3) in vitro stimuliert. Ein 11-Farben-
Panel wurde etabliert, um die simultane Expression der Differenzierungsmarker CD45RA und 
CD27 und der Aktivierungsmarker CD40L, IFNγ, IL2 und TNF auf T-Zellen 
durchflusszytometrisch zu untersuchen. Die Ergebnisse wurden als Absolutwerte in Zellen pro 
ml Blut und als Prozent der jeweiligen Referenzpopulation analysiert.  
Die Ergebnisse dieser Arbeit zeigten, dass die antigenabhaengige Differenzierung der 
Gedaechtnis-T-Zellen mit zunehmendem Alter und CMV-Infektion zunahm. Die 
Differenzierung der Gedaechtnis-T-Zellen in CMV-positiven Spendern war ausserdem mit der 
Antwortgroesse gegen das CMV-Protein pp65 korreliert. Aeltere Spender mit grossen CMV-
spezifischen T-Zell-Antworten hatten die am weitesten differenzierten T-Zellen. Differenzierte 
T-Zellen zeigten eine Herabregulation der Oberflaechenmolekuele CD3, CD4 und CD8 
verglichen mit naïven T-Zellen.  
Die pp65-spezifische, aber nicht die IE1-spezifische T-Zell-Antwort nahm mit zunehmendem 
Alter der Probanden zu. Diese T-Zell-Antworten waren mit zunehmender Groesse auch 
zunehmend polyfunktional, das heisst, sie produzierten mehrere der untersuchten 
Aktivierungsmarker gleichzeitig. Polyfunktionale T-Zellen nach antigenspezifischer und nach 
polyklonaler Stimulation exprimierten qualitativ und quantitativ mehr Aktivierungsmarker pro 
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T-Zelle und  zeigten eine Herabregulation der Oberflaechenmolekuele CD3, CD4 und CD8. Dies 
deutet auf eine staerkere Aktivierung der polyfunktionalen T-Zellen hin.  
Desweiteren konnte gezeigt werden, dass CMV-Infektion einen Einfluss auf andere T-Zell-
Antworten hat. Die T-Zell-Antworten nach antigenspezifischer (PPD) und polyklonaler (OKT3) 
Stimulation waren groesser in CMV-infizierten als in nichtinfizierten Probanden. Dieser Anstieg 
war bedingt durch mehr aktivierte TEM-Zellen in CMV-infizierten Personen. 
Zusaetzlich wurde der Effekt der  immunsupprimierenden Medikamente CyclosporinA (CSA) 
und Takrolismus (FK506) auf polyfunktionale CMV-spezifische T-Zellen untersucht. Die in 
vitro Inkubation von PBMC mit CSA und FK506 resultierte in einem massiven Verlust von 
polyfunktionalen T-Zellen nach Stimulation mit pp65. In pp65-spezifischen T-Zellen inkubiert 
mit CSA oder FK506 konnte nur Degranulation nachgewiesen werden, aber keine anderen 
Aktivierungsmarker.   
Zusammenfassend kann gesagt werden, dass CMV einen grossen Einfluss auf das Immunsystem 
gesunder Individuen hat. Die Differenzierung der Gedaechtnis-T-Zellen ist nicht nur abhaengig 
von der Infektion mit CMV, sondern auch davon, wie das Immunsytem  auf CMV reagiert. 
Polyfunktionale CMV-spezifische T-Zellen, die wahrscheinlich CMV kontrollieren, sind 
vorhanden und werden nicht von dysfunktionalen T-Zellen im Alter verdraengt.  
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3 Abbreviations 
aa    Amino acids 
Ab    Antibody 
AIDS   Aquired immune deficiency syndrome 
APC     Antigen presenting cell 
APC    Allophycocyanin 
APC-Cy7   Allophycocyanin cyanin7 
APC-H7   Allophycocyanin cyanin dye 
Aqvid   Aqua viability dye 
ATG    Anti-thymocyte globulin 
BCG    Bacillus Calmette-Guérin, vaccine prepared from Mycobacterium bovis, 
BFA     Brefeldin A  
BSA    Bovine serum albumine 
CBA    Cytokine bead array 
CCL    Chemokine ligand  
CCR    Chemokine receptor 
CD    Cluster of differentiation 
CD40L   CD40-ligand 
CFSE   Carboxyfluorescein succinimidyl ester 
CI    Confidence intervall 
CMV   Cytomegalovirus 
CSA    Cyclosporin A 
CTL    Cytotoxic T lymphocyte 
DMSO    Dimethyl sulfoxide 
EBV    Epstein-Barr virus 
EDTA    Ethylenediaminetetraacetic acid 
FACS   Fluorescence activated cell sorter 
FCS     Fetal calf serum  
FITC      Fluorescein isothiocyanate 
FK506   Tacrolimus 
FMO control  Fluorescence minus one control 
FSC    Forward scatter  
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g     Centrifugal force 
h     Hour 
HIV    Human immunodeficiency virus 
HLA     Human leucocyte antigen 
ICS    Intracellular cytokine staining 
IE    Immediate early protein  
IFN    Interferon  
Ig    Immunoglobulin  
IL     Interleukin 
IRP    Immune risk profile 
IQR    Interquartile range 
LAMP   Lysosomal-associated membrane protein 
LPS    Lipopolysaccharide 
M. tuberculosis  Mycobacterium tuberculosis 
MFI    Mean fluorescence intensity 
MHC    Major histocompatibility complex 
min     Minute 
MIP    Macrophage inflammatory protein 
ng    Nanogram 
NK cells   Natural killer cells 
PB    Pacific blue 
PBMC    Peripheral blood mononuclear cells 
PBS     Phosphate buffered saline 
PE     Phycoerythrin 
PECy7   Phycoerythrin cyanine dye 
PerCP    Peridinin chlorophyl protein 
PFA    Paraformaldehyde 
PMT    Photomultiplier 
pp65    Phosphoprotein 65 
PPD    Purified protein derivate of M. tuberculosis 
Qdot605   Quantum Dot 605 
RS    Spearman’s correlation coefficient 
ROC curve   Receiver operating characteristics curve 
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RPMI medium  Roswell Park Memorial Institute Medium  
RT     Room temperature 
SEB    Staphylococcal enterotoxin B  
SEM    Standard error of mean 
SSC     Sideward scatter 
Std    Standard deviation 
TCM cell   Central memory T cell 
TCR     T cell receptor 
TEM cell   Effector memory T cell 
TEMRA cell     Effector memory revertant T cell 
TN cell    Naïve T cell 
TNF    Tumour necrosis factor 
Treg    Regulatory T cell 
μg    Mikrogram 
μl    Mikroliter 
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Innate immunity is used to rapidly generate an initial response against pathogens, either 
eliminating it or containing it until the adaptive immune response can develop. A second 
exposure to the same antigen provokes the same immune response as the first encounter. The 
advantage is that the pathogens can be immediately attacked every time they invade the host. 
Innate immunity limits pathogen entry, induces local inflammatory responses, prevents the 
establishment of infection and clears both host and microbial debris.  
4.1.2 Adaptive immunity  
Adaptive immunity is only found in vertebrates and refers to antigen-specific defence 
mechanisms that take several days to become protective [1]. The adaptive immune response is 
maintained by highly specific lymphocytes called B cells (humoral immune response) and T 
cells (cell-mediated immune response). Each lymphocyte clone expresses cell surface receptors 
of a single specificity. After specific activation these cells proliferate and form clones of cells 
with identical surface receptor specificity. The repertoire of receptor specificities is very diverse 
because it is encoded by genes that undergo random somatic rearrangement during lymphocyte 
development [2]. The downside to the specificity of adaptive immunity is that only a very few B 
and T cells in the body recognise a given antigenic determinant (epitope). These few cells then 
must rapidly proliferate in order to produce enough cells to mount an effective immune response 
against that particular epitope, which takes a few days. Binding of the receptor to the 
complimentary antigen is required to activate the cell. B cells are activated by antigen that binds 
directly to the B cell receptor. Activated B cells differentiate into plasma cells, which secrete 
antibodies specific for the antigen. Only a few activated B cells will survive the subsequent 
contraction phase and differentiate to long term memory B cells. These memory B cells allow 
the mounting of a fast adaptive immune response to a second encounter with the same antigen. T 
cells can only be activated by antigen that is processed and presented by antigen-presenting cells 
(APC). The antigens are presented to T cells as a peptide bound to the major histocompatibility 
complex (MHC) of the APC.  
4.2 T cells 
4.2.1 Classification of T cells by lineage markers 
T cells are a major part of the adaptive immune system and are characterised by the expression 
of the T cell receptor (TCR). The peripheral T cell pool is formed from thymic output and 
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includes T cells with various differentiation stages and functional properties. The peripheral T 
cell pool can be divided into smaller subsets based on the expression of surface molecules and 
the properties of single cells. T cells can be distinguished by the type of TCR expressed, with 
about 90% of T cells expressing an αβ-receptor and a minority of T cells expressing the γδ-
receptor [3]. T cells with the γδ-TCR have been characterised to a lesser extent and will not be 
considered in this work. T cells expressing the αβ-TCR can be further divided regarding the 
expression of the accessory molecules, CD4 and CD8, on the cell surface. CD4 T cells recognise 
MHC class II which are expressed on APC and CD8 T cells recognising MHC class I molecules 
which are expressed on most nucleated cells [4]. CD8 T cells are also called cytotoxic T cells 
(CTL) and are responsible for killing tumour and infected host cells by the secretion of cytokines 
and perforin- and granzyme-mediated cytotoxicity [5]. CD4 T cells can be further differentiated 
into several subpopulations depending on their surface markers and their ability to produce 
cytokines and chemokines. The majority of CD4 T cells secrete cytokines which promote the 
activation of professional APC (e.g. macrophages, dendritic cells), B cells and CD8 T cells. A 
small subset of CD4 T cells can dampen the immune response and are therefore called regulatory 
T cells (Treg) [6]. Some CD4 T cells exhibit cytotoxic functions and can lyse other host cells [7, 
8].  
4.2.2 Classification of T cells by phenotype and differentiation 
T cells that have been released from the thymus and not yet encountered their cognate antigen 
are termed naive T (TN) cells until they come across their antigen for the first time. TN cells are 
the most homogenous subpopulation of T cells, lacking most effector functions. The binding of 
the specific antigen, presented by an APC to a TCR, and costimulatory signals lead to T cell 
activation, clonal expansion and the generation of effector T cells. Short-lived effector T cells 
migrate to peripheral tissues and display immediate effector functions early during primary 
infection [9]. After clearance of the antigen most effector T cells die and only a few will remain 
to protect the body against recurrence with the same pathogen [10]. These long-lived memory T 
cells provoke a faster immune response after new antigen encounter than their TN cell precursors 
[11]. Both effector and memory T cells need lower levels of TCR engagement and costimulation 
than TN cells, which enable them to eliminate pathogens faster. Memory T cells can be divided 
into two major subpopulations, central memory T cells (TCM) and effector memory T cells (TEM). 
TCM cells express lymph node-homing receptors, efficiently stimulate APC, lack immediate 
effector functions but differentiate to effector T cells after proliferation. In contrast, TEM cells 
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4.2.4 Effector mechanisms of T cells 
Although CD4 and CD8 T cells are distinct T cell subsets, they possess overlapping functions 
that can be grouped into early, intermediate and late functions [29]. Calcium flux and 
phosphorylation of signalling proteins are induced immediately after activation and are therefore 
early functions, while intermediate functions such as cytokine production and degranulation 
occur a few hours after stimulation. Late functions include proliferation and apoptosis and can 
only be detected hours to days after stimulation [29]. In this work, intermediate functions were 
investigated.  
Cytokines are small molecules (<30 kD) secreted by cells of the immune system which carry 
signals between cells. These immunomodulating proteins, peptides and glycoproteins include 
interleukins, interferons and chemokines. Each cytokine reacts with a receptor on the surface of 
the same or another cell. Binding of the cytokine to the receptor triggers a cascade of 
intracellular signalling which leads to the up and/or downregulation of several genes and their 
transcription factors. This can result in proliferation, production or inhibition of other cytokines, 
surface receptors or even suppression of their own effect. The cytokine network is very complex 
and includes several positive and negative feedback loops, antagonistic and agonistic 
relationships, pleiotropy and redundancy. Half-lives of cytokines are generally very short which 
means that new transcriptions and translations are needed for each new stimulus. All these 
mechanisms help maintain the delicate balance of cytokines to orchestrate the immune response 
against pathogens without harming the body [1].  
In this work, the following activation markers were analysed in detail: IFNγ, TNF, IL2, CD40L 
and CD107a. IFNγ has antiviral and antiproliferative activities and influences other immune 
cells. It binds to the IFNγ receptor which is expressed on all cells except erythrocytes. IFNγ can 
induce the activation of macrophages, upregulate the expression of surface molecules (e.g. MHC 
class I, MHC class II and B7), influence endogenous antigen processing and promote or inhibit 
apoptosis. IFNγ is mainly produced by activated CD4 T cells but also by CD8 T cells and NK 
cells [1]. TNF is a pleiotropic cytokine which has inflammatory, toxic and immunoregulatory 
effects. TNF is involved in systemic inflammation but its most important effect is the regulation 
of immune cells. TNF is produced by many cell types upon different stimuli and in various 
physiological and pathological conditions [1]. T cells which are activated by antigen-binding and 
CD28 costimulatory signals are the main source of IL2. IL2 is secreted following autocrine 
signalling and functions as a T cell chemoattractant. It stimulates the proliferation of activated 
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leucocytes and promotes the differentiation of CD8 T cells and B cells. It is also important for 
the induction of self-tolerance and homeostasis. [1]. CD40L, also known as CD154, is primarily 
expressed as a costimulatory surface molecule on activated CD4 T cells. It can also be found on 
B cells, NK cells, macrophages, mast cells, non-haematopoetic cells as well as in a soluble form. 
CD40L binds to CD40 on APC and thereby triggers their activation in association with TCR 
stimulation by MHC molecules. CD40L is transiently upregulated in activated CD4 T cells and 
can therefore be used as a marker for antigen-specific stimulated CD4 T cells [30, 31]. CD107a 
and b, also known as lysosomal-associated membrane protein-1 and 2, are proteins located in the 
cytotoxic granule membrane which become transiently expressed on the T cell surface upon 
granule exocytosis. Therefore CD107a can be used as a marker for degranulation [32, 33]. 
4.2.4.1 Detection of activated T cells by flow cytometry 
Currently several tools are available for the detection of antigen–specific T cells by flow 
cytometry. To date, flow cytometry is the most sophisticated method available to analyse T cells 
with the possibility to simultaneously measure several read-outs on the same cell. Flow 
cytometric methods include intracellular cytokine staining (ICS), MHC-class-I tetramers and 
dextramers, measurement of proliferation by CFSE or PKH dyes, PhosFlow and degranulation 
assays [33-39]. These assays have sufficient sensitivity to measure rare cell populations which is 
necessary if antigen-specific T cell responses are investigated.  
The measurement of intracellular cytokines in T cells after stimulation by flow cytometry was 
first done by Waldrop et al. (1997) to analyse CD4 T cell responses to Cytomegalovirus (CMV) 
lysate  [40]. ICS measured by flow cytometry allows multiparametric analysis on a single cell 
level and relies on short term in vitro stimulation of peripheral blood mononuclear cells (PBMC) 
(Figure 5). Viral lysates, whole proteins, single peptides and peptide pools spanning whole 
proteins can be used for antigen-specific stimulation of T cells in vitro. Lysates and proteins 
have to be internally processed by APC before being presented on MHC class I or MHC class II 
molecules, whereas peptides can be directly taken up by MHC class I or MHC class II molecules 
and presented to the T cells. Peptides with a length of 8-10 amino acids (aa) are optimised to 
stimulate CD8 T cells via MHC class I and longer peptides (15-30 aa) are optimised to stimulate 
CD4 T cells. In addition, T cells can be polyclonally stimulated by superantigens, antibodies or 
mitogens. In this study, pools of overlapping peptides spanning whole proteins were used. They 
cover all potential epitopes in the proteins and stimulate both CD4 and CD8 T cells [41, 42]. 
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4.3 Cytomegalovirus (CMV) 
CMV is a member of the human herpesvirus family which includes the herpes simplex virus, 
Epstein-Barr virus (EBV), varicella-zoster virus and human herpesvirus 5-8. Herpesviruses are 
usually characterised by an asymptomatic acute infection followed by lifelong persistence in the 
human host. Human CMV is highly prevalent in most populations (50-90% seropositivity in 
developed countries and almost 100% in developing countries). During active infection, the virus 
is excreted in body fluids, such as urine, saliva, breast milk and semen (rev. in [46]). Infection 
usually occurs in early childhood from both vertical and horizontal transmission or in young 
adults by sexual transmission [47]. The infection rate in adults is about 1% per year [48]. 
Although CMV is usually acquired as an asymptomatic infection at young age, if infection 
occurs before birth, the consequences can be severe. Congenital CMV is the most common 
infectious form of congenital birth defects. The prevalence is 0.15-2% worldwide and 10-20% of 
babies with congenital CMV infection will exhibit neurological damage (rev. in [49]).  
An active CMV infection is defined by detectable viral replication or a significant rise in CMV-
specific antibodies. Active infection can be a primary infection in a previously seronegative 
individual or a reactivation in a seropositive individual. If there is no active replication of the 
virus in the host the infection is latent. CMV disease is the clinical expression of active infection 
[50].  
CMV infects mainly epithelial and endothelial cells, fibroblasts and leucocytes. In the case of 
CMV disease, the virus can be found in all organs (rev. in [46]). CMV replicates very slowly in 
cell culture and in vivo. The life cycle of CMV can be divided into three phases: immediate early 
(IE), early, and late. The IE genes are transcribed after virus entry and rely on host factors for 
expression. Following the IE stage, the early gene products are transcribed and include DNA 
replication proteins and some structural proteins. Finally, the late gene products are transcribed. 
These are mainly structural proteins that are involved in virion assembly and shedding of the 
virus. Formation of the capsids occurs in the nucleus of the host cell and accumulation of these 
particles results in the typical “owl’s eye” appearance [51].  
4.3.1 CMV-specific immune response 
CMV is a large icosahedral beta-herpesvirus with a 230 kb double-stranded DNA genome with 
213 known open reading frames, including 151 open reading frames whose protein products are 
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immunogenic for CD4 and/or CD8 T cells [52]. The immune response is not directed evenly 
against all CMV proteins but is clearly focused. Two of the most immunogenic proteins are the 
phosphoprotein 65 (pp65) and the IE protein 1 (IE1) [52-58].  The structural pp65 accumulates 
in both nucleus and cytoplasm of infected cells as the virus matures late in infection while IE1 is 
a non-structural protein, which is expressed as one of the first CMV-antigens in an infected cell.  
Healthy immunocompetent individuals produce anti-CMV immunoglobulin (Ig) M during 
primary infection, which persists for 3-4 months (rev. in [46]). IgG are produced a few weeks 
later and persist for life. It has been shown that in primary asymptomatic CMV infection, CMV-
specific CD4 T cells appear 10 days after CMV DNA is detectable. This is followed, 14 days 
later, by the appearance of CMV-specific CD8 T cells [59]. T cell responses to CMV proteins 
are both advantageous and harmful for the human body. T cell responses are protective against 
CMV disease but these responses also result in massive clonal expansion of CD8 T cells which 
compromise host immunity to other infections (rev. in [60]). Reactivation of the latent virus is 
rare in immunocompetent people and appears to be linked to immune activation and stress. 
Examples include astronauts during space flights [61, 62], patients in intensive care units [63], 
after septic shock [64] and patients with Guillain-Barré syndrome [65]. In healthy people, the 
CD4 and CD8 T cell responses are sufficient to control, but not eradicate the virus.  
Millions of years of co-evolution between CMV and humans have enabled the virus to develop 
mechanisms to modulate the human immune system to survive in the host. Although the host 
launches a strong immune response against it, CMV is able to establish lifelong persistence. 
CMV encodes proteins that can influence both the innate and the adaptive immune responses. 
The proteins include cytokine homologues, chemokine receptor homologues and chemokine 
binding proteins. CMV can limit the complement cascade, lessen the effects of IFN activation, 
interfere with NK cell activity, induce anti-inflammatory responses with an IL10 homologue and 
prevent apoptosis. CMV can also impair T cell activation by dampening the release of IFNγ and 
TNF from PBMC and downregulating the expression of MHC class I and II (rev. in [66-68]). All 
of these CMV-mediated modulations result in nonspecific inhibition of cellular and humoral 
immune responses. This suggests that the virus may employ mechanisms that make the host 
susceptible to other types of infection. The crucial role of the immune system to control CMV 
infection can be observed in immunocompromised individuals in which CMV infection or 
reactivation causes serious and often life-threatening complications, particularly in transplant 
recipients and patients with aquired immune deficiency syndrome (AIDS). CMV disease is one 
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of the most frequent opportunistic infections in patients with advanced human immunodeficiency 
virus (HIV) infection, of whom 40% develop life threatening CMV disease (rev. in [69]). 
Additionally, in HIV-co-infected individuals, CMV appears to be related to enhanced 
progression of AIDS (rev. in [70]). Another group with a high risk of severe CMV disease are 
recipients of transplants [71, 72]. Immunosuppressive treatment following solid organ 
transplantation weakens the immune response to CMV. As a result high numbers of patients are 
at risk of CMV associated diseases which can be lethal. More than 50% of transplant recipients 
show evidence of CMV replication in the first year post-transplantation [73]. CMV infection is 
therefore the most common opportunistic infection after solid organ transplantation and causes 
both direct and indirect morbidity [74, 75]. Direct effects are caused by the virus and include 
nephritis, hepatitis, colitis and myocarditis. Indirect effects are caused by the interaction between 
virus and host immune system and are associated with an increased risk of graft rejection, 
opportunistic infections and decreased recipient survival [72, 76].  
4.3.2 CMV and Immunosenescence  
The terms ‘immune-ageing’ or ‘immunosenescence’ describe a combination of features affecting 
the functions and phenotypes of immune cells in older age. Older people will have survived 
numerous infections and therefore have an increased number of memory cells which should 
enable them attack a previously encountered antigen more effectively. Unfortunately, rather than 
the immune system becoming more effective with age, at some stage it starts becoming less 
effective. By comparison with the younger population, many diseases in the elderly are more 
frequent and more severe. Older individuals are more likely to suffer from vaccine failure and 
infections caused by both latent carried and newly encountered pathogens, including urinary tract 
infections, respiratory infections, skin infections, varicella-zoster reactivation and tuberculosis 
(rev. in [77-79]). Immunosenescence is multi-factorial and so far not completely understood. 
Normal ageing is determined genetically but external factors also affect ageing in general and 
immunosenescence in particular. Published research in this field suggests that latent viral (e.g. 
CMV) infections also contribute to immunosenescence [80-86]. 
The innate and adaptive immune responses are both affected by the ageing process but the most 
profound alterations are described in the adaptive response, specifically in T cell immunity 
(Table 1, rev. in [87-90]). The differences in T cell immunity attributed to ageing include 
changes on the single cell level as well as changes in T cell populations. The diversity of the 
TCR is reduced in old people which might explain the impaired T cell immunity to new 
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infections [91]. The declining output of T cells by the thymus also contributes to 
immunosenescence. Although T cells are produced continuously throughout life, in elderly 
people the degradation of the thymus causes a sharp decrease in the number and type of TN cells 
produced. Additionally the capacity for renewal of haematopoietic stem cells declines with age. 
Repeated exposure to antigen induces more differentiated T cells and accelerates T cell ageing. It 
appears that chronic infections (e.g. CMV, EBV) play an important role because T cells are 
constantly reactivated [92, 93]. Taken together, this results in an altered memory T cell subset 
distribution with less TN cells and more differentiated T cells with a reduced TCR diversity in 
older people [94, 95]. While the adaptive immune system weakens with age, at the same time an 
elevated inflammatory response and a chronic systemic pro-inflammatory state, called inflamm-
ageing, can be observed [96]. The parallel deterioration of T cell immunity and the upregulation 
of the innate immunity might be explained by recent reports suggesting that T cells are necessary 
to regulate the innate immune response (rev. in [97]).  
Innate immunity Adaptive immunity 
− Increased inflammatory background 
(Inflamm-ageing) 
− Impaired antigen-uptake and 
presentation by APC 
− Impaired macrophage functions 
− Reduced NK cell cytotoxity 
 
− Decreased naive T cell output by 
thymus 
− Accumulation of effector and memory 
T cells 
− Restricted T cell repertoire 
− Reduced B cell production 
− Impaired B cell functions 
− Decreased CD4/CD8 T cell ratio 
Table 1: Age-related changes of the immune system 
 
Swedish longitudinal studies in elderly individuals have shown that immunological parameters 
can be used to predict mortality [98, 99]. Low CD4/CD8 ratio, poor proliferative response and 
high numbers of CD28- T cells are associated with CMV and contribute to the immune risk 
profile (IRP) which is highly associated with mortality in older people. Although studies did not 
show a direct correlation between CMV infection and mortality, the results suggest a 
contribution of the virus to risk factors that correlate with mortality (rev. in [80, 84]). It is still 
unclear to what extent persistent viral infection in general and CMV in particular contribute to 
immunosenescence. 
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To gain more information about the complex interaction of the ageing immune system and CMV 
infection, experiments were performed on PBMC from CMV-seropositive and CMV-
seronegative people in three different age groups. Phenotypes and functionality of antigen-
specific and polyclonally stimulated PBMC were investigated by multicolour flow cytometry. 
The expression of the phenotypic markers CD45RA and CD27 and activation markers CD40L, 
IFNγ, IL2 and TNF were analysed on CD4 and CD8 T cells.  
Furthermore, the in vitro effect of immunosuppressive drugs on polyfunctional CMV-specific T 
cells was analysed to expand the understanding of CMV reactivation in transplant patients. For 
this purpose, PBMC from CMV-seropositive donors were incubated overnight with 
immunosuppressive drugs and subsequently stimulated with pp65. In addition to the 
aforementioned activation markers, expression of CD107 as a marker of degranulation was also 
analysed. 
 
Materials and Methods  26 
5 Materials and Methods  
5.1 Materials  
5.1.1 Reagents 
Dimethyl sulfoxide (DMSO)    Pierce, Rockford, USA 
Ficoll-PaqueTM PLUS    Biochrom AG,Berlin, Germany 
Trypan blue       Biochrom AG,Berlin, Germany 
Acetic acid      Merck, Darmstadt, Germany 
Bovine Serum albumine (BSA)  Serva, Heidelberg, Germany 
Natriumazid (NaNH3)    Serva, Heidelberg, Germany 
Brefeldin A       Sigma, USA 
GolgiStop       BD, San Jose, CA, USA 
Ethylenediaminetetraacetic acid (EDTA) Sigma, USA 
FACSFlow      BD, San Jose, CA, USA 
FACS Lysing Solution      BD, San Jose, CA, USA 
FACS Permeabilizing Solution   BD, San Jose, CA, USA 
Fetal calf serum (FCS)    Biochrom AG,Berlin, Germany 
Phosphate buffered saline (PBS)  PAA, Pasching, Austria 
Paraformaldehyde (PFA)   Biochrom AG,Berlin, Germany 
Penicillin       Biochrom AG,Berlin, Germany 
Streptomycin      Biochrom AG,Berlin, Germany 
L-Glutamine      Biochrom AG,Berlin, Germany 
Cyclosporine A (CSA)    Sigma, USA 
Tacrolimus (FK506)    Sigma, USA 
Rainbow Beads     BD, San Jose, CA, USA 
Cytometer Setup Tracking (CST) Beads BD, San Jose, CA, USA 
CompBeads     BD, San Jose, CA, USA 
5.1.2 Media and buffer 
RPMI 1640 Medium     Biochrom AG,Berlin, Germany 
Complete media  RPMI 1640 Medium, 100 U/ml Penicillin, 100 U/ml 
Streptomycin, 2 mM L-Glutamin, 10% FCS  
Fixation buffer      0.5% PFA in PBS 
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FACS wash buffer     PBS, 0.5% BSA, 0.1% NaNH3 
5.1.3 Peptides and stimulants 
PPD       Kind donation of Prof. Volk, Charite Berlin 
pp65 spanning peptide pool   JPT, Berlin, Germany 
IE-1 spanning peptide pool   JPT, Berlin, Germany 
OKT3 Kind donation of Prof. Lehmkuhl, Deutsches 
Herzzentrum Berlin 
5.1.4 Laboratory Equipment 
Sterile hood      Heraeus, Buckinghamshare, UK 
Vortex       Scientific Industries, USA 
Haemocytometer     Neubauer Improved  
Incubator      Heraeus, Buckinghamshare, UK 
Centrifuge 5810,     Eppendorf, Wesseling-Berzdorf, Germany 
Centrifuge CR422,     Jouan, Fernwald, Germany 
Centrifuge Z160M     Hermle, Gosheim, Germany 
Centrifuge Multifuge 3    Heraeus, Buckinghamshare, UK 
Flow Cytometer LSRII    BD, San Jose, CA, USA 
Flow Cytometer FACSCalibur   BD, San Jose, CA, USA 
Pipetus       Hirschmann, Heilbronn, Germany 
Pipettes         Corning Costar Incor., New York, USA 
Pipette tips      Sarstedt, Nürnbrecht, Germany  
Microcentrifuge tubes    Eppendorf, Wesseling-Berzdorf, Germany 
Polypropylen tubes    Sarstedt, Nürnbrecht, Germany    
FACS-tubes     Sarstedt, Nürnbrecht, Germany 
Cell Strainer     BD, San Jose, CA, USA 
5.1.5 Software 
Flowjo 6.3.1     Treestar, Ashland, USA 
FacsDiva 7      BD, San Jose, CA, USA 
SPSS 16.0      SPSS Inc, Chicago, USA 
5.1.6 Kits 
QDot605 Konjugation Kit   Invitrogen, Carlsbad, USA 
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5.1.7 Antibody panels 
Laser Excitation Emission Fluorochrome Antigen Clone Amount Distributor 
blue 
480 613 ECD CD4 SFCI12T4D11 2 μl Beckman Coulter 
490 675 PerCP CD45 2D1 20 μl BD 
696 719 APC-H7 CD8 SK1 3 μl BD 
violet 403 455 PB CD3 OKT3 1 μl Biolegend 
Table 2: Staining reagents for the whole blood staining  
 
Laser Excitation Emission Fluorochrome Antigen Clone Amount Distributor 
blue 
494 520 FITC CD16 3G8 5 μl BD 
480 578 PE CD27 L128 5 μl BD 
480 613 ECD CD45RA MB1 5 μl Beckman Coulter 
490 675 PerCP CD4 SK3 15 μl BD 
480 767 PECy7 IFNγ B27 4 μl BD 
red 
650 660 APC IL2 5344.111 5 μl BD 
650 767 Alexa700 TNFa Mab11 3 μl BD 
696 719 APC-H7 CD8 SK1 3 μl BD 
violet 
403 455 PB CD40L 24-31 0.5 μl Biolegend 
367 526 Aqvid   0.75 μl Invitrogen 
405 605 Qdot CD3 OKT3 1 μl Invitrogen 
 Table 3: Staining reagents for the CMV study 
 
Laser Excitation Emission Fluorochrome Antigen Clone Amount Distributor 
blue 
494 520 FITC CD107a H4A3 10 μl BD 
480 578 PE CD40L TRAP1 10 μl BD 
480 613 ECD CD4 SFCI12T4D11 2 μl Beckman Coulter 
red 
650 660 APC IL2 5344.111 5 μl BD 
650 767 Alexa700 TNFa MAb11 3 μl BD 
696 719 APCH7 CD8 SK1 3 μl BD 
violet 
403 455 PB CD3 OKT3 1 μl CambridgeBioscience 
367 526 Aqvid   0.75 μl Invitrogen 
Table 4: Staining reagents for the experiments with immunosuppressants 
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5.2 Methods 
5.2.1 PBMC Preparation 
Heparinised blood was diluted with sterile PBS (1:1) and carefully layered onto Ficoll. Tubes 
were centrifuged (20 min, room temperature (RT), 1000 x g, no brakes, low acceleration) and 
PBMC were aspirated and washed twice with 50 ml sterile PBS (10 min, RT, 300 x g). PBMC 
were diluted in complete medium to a final concentration of 5x106 PBMC/ml. 
5.2.2 Qdot-Conjugation OKT3 
CD3 antibodies (Ab) conjugated to QDot605 were not available at the beginning of the study 
therefore CD3 (OKT3) Ab were conjugated with the help of a QDot conjugation Kit (Invitrogen) 
according to the manufacturer’s instructions.  All steps were done at RT. Briefly, QDots were 
activated with 1 mM succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate for 1 h 
while 300 µl Ab were reduced with 20 mM dithiothreitol for 30 min. QDots and Ab were filtered 
separately by using NAP-5-columns, 500 µl of each were collected, mixed and conjugated for 1 
h. The conjugation was quenched by adding β-Mercaptoethanol for 30 min at RT. The QDot-Ab-
conjugate was concentrated using ultrafiltration devices and separated from the unconjugated Ab 
with a separation column.  
5.2.3 Whole Blood Count 
Heparinised whole blood was diluted 1:20 in 3% acetic acid and white blood cells were counted 
using a haemacytometer to enable the calculation of absolute cell numbers per ml blood.  
5.2.4 Whole Blood Staining Procedure  
Whole blood (100 μl) was incubated with Ab specific for surface markers (30 min, 4˚C). Red 
blood cells were lysed with 1 ml BD Lyse (10 min, RT). Following lysis cells were washed with 
3 ml washing buffer and acquired immediately.  
5.2.5 Stimulation 
PBMC (2 x 106) were incubated for 2 h (37˚C, 5% CO2) in 0.5 ml complete RPMI media and 
either 1 µg/ml pp65 peptide pool, 1 µg/ml IE-1 peptide pool, 10 µg/ml PPD, 0.5 µg/ml OKT3 as 
positive control or an equivalent amount of DMSO as negative control. After 2 hours of 
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incubation, Brefeldin A (10 µg/ml) was added and the volume was adjusted to 1 ml (complete 
media). Cells were then incubated for 14 h (37˚C, 5% CO2). 
5.2.6 Incubation with immunosuppressants 
PBMC (2 x 106) were incubated overnight (37˚C, 5% CO2) in 1 ml complete media in the 
presence of FK506 (2 ng/ml, 10 ng/ml or 50 ng/ml), CSA (40 ng/ml, 200 ng/ml or 1000 ng/ml) 
or without immunosuppressant. After 16 hours cells were washed with complete RPMI media 
and resuspended in 500 µl of complete RPMI media with 10 µl CD107a-FITC, 1 µl Golgistop 
and 1 µg/ml pp65 spanning peptide pool or an equivalent amount of DMSO. After 2 hours of 
incubation 2 µl Brefeldin A (5 mg/ml working solution in DMSO) were added and the volume 
adjusted to 1 ml (complete media) for the last 4 hours. 
5.2.7 Immunofluorescence Staining Procedure 
Following stimulation, cells were incubated with 20 mM EDTA in PBS. Cells were washed 
using wash buffer and incubated with pre-titered surface antibodies for 30 min at 4˚C in the dark. 
Cells were washed, lysed with BD Lyse and permeabilised with BD Perm2 solution according to 
the manufacturer's instructions (BD Bioscience). Following permeabilisation cells were stained 
intracellularly for 30 min at 4˚C in the dark with pre-titered antibodies. Cells were washed, fixed 
in fixation buffer and analysed by flow cytometry. 
5.2.8 Flow Cytometric Analysis  
FlowJo 8.8.6 software was used for data analysis. Lymphocytes were gated in a side scatter 
(SSC) vs. forward scatter (FSC) gate and doublets were excluded using FSC-height vs. FSC-
area. Live cells were gated using aqua viability dye (aqvid) and NK cells were excluded by 
gating out bright CD16/CD56 cells. CD3- cells were excluded by gating CD3 against CD4 and 
CD8 cells were excluded by gating CD4 against CD8. To take into account the downregulation 
of CD4 on activated cells, CD4 T cells were gated against each activation marker and then 
combined into one CD4 T cell population. The same strategy was applied for CD8 T cells. CD4 
and CD8 T cells were analysed separately regarding their CD45RA and CD27 expression as well 
as their expression of the four activation markers (CD40L, IL2, TNF, IFNγ) in all possible 
combinations. The four subsets CD45RA+CD27+, CD45RA-CD27+, CD45RA-CD27- and 
CD45RA+CD27- were also analysed in respect to their activation markers. The four activation 
markers were gated against CD4 or CD8. The gating strategy is shown in Figure 6 and Figure 7.  
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interval (CI). In scatter plots, each dot represents an individual donor and a linear regression line 
is shown. Box plots display the median, interquartile range (IQR, difference between the 75th 
and 25th percentiles), minimum, maximum, outlier (•, more than 1.5 IQR away from 75th and 
25th percentiles) and extreme values (*, more than 3 IQR away from 75th and 25th percentiles). 
Improvements in flow cytometric methods, especially polychromatic intracellular flow 
cytometry, enable researchers to generate millions of data points simultaneously for individual 
samples. In this study the investigation of four different activation markers at the same time 
resulted in 16 exclusive combinations of activation markers. One population consisted of 
quadruple negative cells which were considered to be non-responding cells. The other 15 
populations included all combinations from single cytokine producers to cells producing all four 
activation markers simultaneously. Since multicolour flow cytometry is a relative new 
technology, there is no consent yet of what statistical methods are best applied. So far, research 
groups have used a variety of different statistical methods to analyse the data and define 
significance between different cell populations.  
One important question was whether the frequencies of cells or absolute numbers per ml blood 
should be analysed. This report uses ‘absolute counts’ for numbers of cells per ml blood and 
‘frequencies’ when indicating the percentage of a subpopulation with respect to the relevant 
reference population (e.g. IFNγ-producing CD4 T cells in percent of all CD4 T cells). The 
analysis of polyfunctional cells is very complex and can be done in several ways which hinders 
direct comparison between data generated in different laboratories. When frequencies are used 
for the analysis, the results depend entirely on the reference population. The same data could 
show either an increase in a specific subpopulation related to all T cells or demonstrate a 
decrease by using all responding T cells as a reference population. If frequencies are used, it is 
fundamental to write precisely what reference population was used (e.g. all CD8 T cells or all 
responding TN CD4 T cells) to interpret the data appropriately. In this work, the frequencies with 
the reference population indicated were used for graphs. In many cases, for comparison, 
supplemental graphs displaying absolute numbers per ml blood are shown in the appendix. 
Analyses were done for both frequencies and absolute numbers per ml blood for the CMV-study. 
Due to the prolonged in vitro incubation with immunosuppressive drugs (which may affect T cell 
umbers), frequencies but not absolute numbers were investigated in the experiments with the 
immunosuppressants.  
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Another important consideration was the large interindividual variations in the same subsets. 
This is especially important considering that some of these subsets were very small (only 
consisting of a few cells) and therefore even small variations had a large impact. The precision of 
the quality of the response is based on the number of cells acquired. The acquisition of higher 
numbers of PBMC would allow the analyses of more responding cells, but the number of 
analysed cells could not be expanded since there were only limited amounts of blood available. 
The cost for reagents would have multiplied if larger amounts of PBMC had been processed and 
analysed. It was unclear if these very small subsets based on a small number of events were 
representing real subsets or if they were false positives and represent non-specificly staining of 
cells. These small subsets could be excluded from the data. However, this would lead to the 
overestimation in the frequencies of the remaining larger subsets and skew the analysis. Subsets 
which existed in less than half the donors came up with zero in the median and therefore did not 
influence final statistical analyses. Small subsets that appeared in more than half the donors were 
likely to be real subsets of cells and were not excluded. Therefore, the only cut-off in this study 
was performed when the frequencies of all responding CD4 or CD8 T cells were below 0.01% of 
all CD4 or CD8 T cells after background subtraction. This cut-off did not exclude any responses 
after OKT3 stimulation in any donor or any pp65-specific responses in CMV-seropositive 
donors.  
The complexity of the T cell response provided a further challenge of the data analyses. The 
investigation of four different activation markers resulted in 15 exclusive cell subsets expressing 
different combinations of activation markers. These 15 populations were examined in the four 
memory subsets and in the total CD4 and CD8 T cell compartment. This resulted in 150 distinct 
populations of activated T cells. For further analysis these populations were grouped together. 
This allowed investigation of e.g. all responding T cells in TEMRA cells, all CD4 T cells that 
produced IFNγ or all CD8 TN cells that synthesised three cytokines simultaneously. All data 
were analysed in terms of percentages and as absolute numbers per ml blood. Taken together, 
1125 different T cell subsets per sample were examined in this work. Additionally, MFIs were 
acquired for phenotypic and activation markers and analysed for several T cell subsets. The data 
were analysed separately for each stimulated sample (DMSO, pp65, IE1, PPD and OKT3) and 
for each stimulated sample with the background subtracted (pp65-DMSO, IE1-DMSO, PPD-
DMSO and OKT3-DMSO) for each of the 50 tested individuals. For this study, more than half a 
million data were analysed, not including the study with the immunosuppressive reagents.  
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6 Results 
6.1.1 Staining Panel Development 
In order to investigate polyfunctional T cell responses an 11-colour reagent panel had to be 
developed. For all experiments, a LSRII flow cytometer with three lasers (excitation lines at 
405nm, 488nm and 635nm), 11 fluorescent detectors and FACSDiva software was used.  
Several factors were taken into consideration for the development of the multicolour staining 
panel [100, 101]. In general, brightest fluorochromes should be used for rare or weakly 
expressed markers of interest (e.g.cytokines) whereas dim fluorochromes could be used for 
dump channels to exclude unwanted cell populations (e.g. B cells, NK cells), or for highly 
expressed, and therefore easily distinguishable, markers (e.g. lineage markers such as CD3, 
CD4).The functional definition of reagent brightness is the stain index which takes into account 
the difference between the positive and negative populations and the spread of the negative 
population. Bright fluorochromes include PE and APC, while APC-H7and PerCP are dim 
fluorochromes. It is important to choose the brightest fluorochromes available and to minimise 
spillover between channels. Spillover negatively affects the cell population, even after 
compensation is applied, and should therefore be minimised from the beginning.  
The first step in the development of the multicolour panel used in this study was the titration of 
every fluorochrome-Ab conjugate. This was done to detect the best concentration to optimise the 
signal-to-noise ratio and minimise background staining. Titration was done under assay 
conditions and at least three different concentrations of each fluorochrome-Ab conjugate were 
tested. Ab for phenotypic markers were titrated on unstimulated cells whereas Ab for activation 
markers were titrated on polyclonally stimulated cells and unstimulated cells in parallel. The 
optimal concentration for each Ab was identified by comparing both background staining and the 
stain index. For each marker, several different fluorochrome-Ab conjugates were tested and 
compared with each other. The best possible fluorochrome-Ab conjugate combination was 
chosen for the panel. High background staining can be caused by dead cells which often bind 
monoclonal Ab non-specifically. A viability dye was used to exclude dead cells from analyses 
and improve the performance. Amine-reactive viability dyes penetrate the damaged cell 
membranes of dead cells, bind to cytoplasmatic components and form stable fluorescent 
aggregates [102, 103]. Finally, the different fluorochrome-Ab conjugates were combined to 
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Compensation controls were always run prior to sample acquisition. Commercially available 
CompBeads were used for the compensation since compensation is specific for the fluorochrome 
and not the cell type [104]. Adjustment of photomultiplier tube (PMT) voltages was done either 
manually, after the acquisition of eight-peak-beads, or automatically by ‘Cytometer setup and 
Tracking’ (CST) following FACSDiva update. The adjustment of PMT voltages was carried out 
to guarantee a consistent and comparable read-out [105]. 
Due to practical limitations, such as instrument optical configuration, commercial reagent 
availability and fluorescence spillover, the following panel was established for the CMV study 
(Table 5). Aqvid was used to exclude dead cells. CD16 and CD56 were used as a dump channel 
to exclude NK cells from the analysis. CD3, CD4 and CD8 were used to identify T cell 
populations. Four different activation markers were analysed to increase sensitivity: CD40L, 
IFNγ, TNF and IL2. The brightest available fluorochromes were used for the four activation 
markers to enable gating of activated T cells. The fluorochromes for differentiation markers 
CD45RA and CD27 were chosen to ensure the best possible separation of the four memory 
subsets without compensation problems. Dimmer fluorochromes were used for the lineage 
markers and the dump channel, since these are highly expressed and can therefore be separated 
with dim fluorochromes.  
Fluorochrome FITC PE ECD PerCP PECy7 APC A700 APC-H7 PB Aqvid QDot 
Antigen CD16,CD56 CD27 CD45RA CD4 IFNγ IL2 TNFa CD8 CD40L 
 
CD3 
Table 5: Staining reagents used in the CMV study 
The study involving immunosuppressive drugs was focused on polyfunctional T cells and not on 
memory differentiation markers, so the panel was altered accordingly (Table 6). CD107a, a 
degranulation marker, was added to investigate a broader range of effector functions. CD40L-PE 
was used because this antibody gave better separation and less background staining than the 
CD40L-PB-conjugate. CD3 and CD4 were used with PB and ECD respectively since these 
conjugates also gave a better separation.  
Fluorochrome FITC PE ECD PECy7 APC A700 APCH7 PB Aqvid 
Antigen CD107a CD40L CD4 IFNγ IL2 TNF CD8 CD3 
 
Table 6: Staining reagents used in the experiments with immunosuppressive drugs 
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6.2 T cells  
To investigate age-dependent changes in T cells, PBMC from 26 young, 12 middle-aged and 12 
old donors were analysed by flow cytometry for relative cell numbers, phenotypic T cell markers 
and intracellular cytokine staining (Table 7). Due to technical problems, absolute numbers of 
cells per ml peripheral blood were only analysed for 24 young, 11 middle-aged and 12 old 
donors. Leucocytes in the peripheral blood were counted and whole blood staining (CD45, CD3, 
CD4 and CD8) was performed, which identifies all white blood cells by the expression of CD45 
and the T cell subsets as a percentage of all CD45+ cells.   
Table 7: Number and age distribution of donors 
 
Absolute counts and frequencies of CD3, CD4, CD8 T cells and CD4/CD8 T cell ratios did not 
differ significantly between the three age groups (Table 8). The absolute numbers of CD4 and 
CD8 T cells per ml blood and the respective frequencies of these subsets in terms of CD3 T cells 
were strongly correlated (RS >0.550, p<0.001 for all tested populations).  
 
Young 20-35 y Middle-aged 35-56y Old 63-84y 
Lymphocyte count (105/ml blood) median (range) 62 (32-111) 50 (42-83) 61 (43-86) 
% CD3 T cells of lymphocytes  median (range) 74 (54-87) 71 (53-76) 73 (44-87) 
% CD4 T cells of CD3+T cells  median (range) 55 (39-71) 63 (43-79) 63 (33-72) 
% CD8 T cells of CD3+T cells  median (range)) 34 (24-44) 29 (19-45) 29 (13-59) 
CD3 T cell count (104/ml blood) median (range) 140 (78-277) 143 (48-231) 158 (87-225) 
CD4 T cell count (104/ml blood) median (range) 73 (45-161) 90 (21-148) 86 (34-130) 
CD8 T cell count (104/ml blood) median (range) 44 (22-94) 40 (22-68) 38 (21-131) 
Ratio CD4/CD8 median (range) 2.1 (0.6-4.2) 2.4 (1.5-4.6) 2.3 (1.1-5.0) 
Table 8: Lymphocyte counts from peripheral blood in three age-groups 
 
Frequencies n Median age (range) 
Young 26 28 (20-35) years 
Middle-aged 12 46 (36-56) years 
Old 12 67 (63-84) years 
   
Absolute counts n Median age (range) 
Young 24 28 (20-35) years 
Middle-aged 11 46 (36-56) years 
Old 12 67 (63-84) years 
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As described previously, absolute counts for CD3, CD4 and CD8 T cells were higher in CMV-
seropositive than CMV-seronegative donors [106-108]. Only the differences for CD3 and CD8 T 
cell counts reached statistical significance (Table 9, p=0.002 and p<0.001 respectively). The 
frequency of CD8 T cells was also significantly higher in CMV-positive than in CMV-negative 
donors (p=0.026). This resulted in a decreased CD4/CD8 ratio (p=0.014) in CMV-infected 
donors. This result is supported by previous investigations [106, 109]. Of note, only one young 
donor in this study had a CD4/8 ratio below 1. 
 
CMV-negative CMV-positive p-value 
N 25 24 
 
Lymphocyte count (105/ml blood)  median (range) 56 (33-94) 60 (32-111) ns 
% CD3+ T cells of Lymphocytes  median (range) 70 (53-85) 73 (44-87) ns 
% CD4+ T cells of CD3+T cells  median (range) 58 (39-79) 52 (33-75 ns 
% CD8+ T cells of CD3+T cells  median (range) 33 (13-45) 39 (22-58) 0.026 
N 24 23 
 
CD3+ T cell count (104/ml blood) median (range) 121 (48-216 152 (87-277) 0.002 
CD4+ T cell count (104/ml blood) median (range) 73 (21-113) 82 (34-161) ns 
CD8+ T cell count (104/ml blood) median (range) 39 (21-80) 59 (35-131) <0.001 
Ratio CD4/CD8 median (range) 2.4 (1.4-5.0) 1.9 (0.6-4.2) 0.014 
Table 9: Lymphocyte counts from peripheral blood in CMV-seronegative and CMV-seropositive donors 
6.3 Memory T cell subsets  
6.3.1 Influence of age on memory T cell subsets 
Memory T cell subsets undergo changes in the course of ageing which are caused by a variety of 
factors including the decline of thymic output and recurring antigen encounters. To investigate 
the memory subsets found in peripheral blood in relation to donor age, PBMC were stained for 
the phenotypic markers CD45RA and CD27 and analysed by flow cytometry. In this work, 
CD45RA+/CD27+ cells will be referred to as naïve T cells (TN cells), CD45RA
-/CD27+ T cells as 
central memory T cells (TCM cells), CD45RA
-/CD27- T cells as effector memory T cells (TEM 
cells) and CD45RA+/CD27- cells as effector memory revertant T cells (TEMRA cells) (Figure 10). 
This is for simplicity and by convention as this nomenclature is used in published reports [14, 
110, 111].  
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The results also indicated that the composition of the memory T cell subsets of responding T 
cells in CMV-positive donors correlated with age and with the response size following 
stimulation with pp65-spanning peptide pools (Figure 22). The frequencies of pp65-specific CD4 
TN (RS =-0.475, p=0.025) and TCM cells (RS =-0.491, p=0.020) were significantly diminished 
while the frequencies of pp65-specific CD4 TEM cells (RS =0.525, p=0.012) expanded with 
increasing response size to pp65 stimulation. The frequencies of pp65-specific CD4 TEMRA cells 
were not significantly correlated with the pp65-specific response size.  
In addition, similar patterns were seen when the entire memory CD4 T cell distribution was 
correlated with the pp65-specific T cell response size. The frequencies of all CD4 TN cells 
(Figure 22, RS=-0.497, p=0.016) were significantly diminished with increasing pp65-specific T 
cell response size while the frequencies of all CD4 TEM cells were expanded (RS=0.446, 
p=0.033). The frequencies of all CD4 TCM and TEMRA cells were not significantly correlated with 
the pp65-specific response size. The degree of advanced T-cell memory differentiation within 
the pp65-specific response, but also in general, therefore, seems to depend on the size of the 
CMV-specific T cell response with small responses having little effect but large responses a big 
effect. 
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CD40L IFNγ IL2 TNF 
pp65-stimulated CD4 T cells 
RS = 0.864, 
p<0.001 
RS = 0.954, 
p<0.001 
RS = 0.148, 
ns 
RS = 0.893, 
p<0.001 
pp65-stimulated CD8 T cells 
RS = 0.889, 
p<0.001 
RS = 0.885, 
p<0.001 
RS = 0.096, 
ns 
RS = 0.870, 
p<0.001 
OKT3-stimulated CD4 T cells 
RS = 0.907, 
p<0.001 
RS = 0.939, 
p<0.001 
RS = 0.238, 
p=0.012 
RS = 0.959, 
p<0.001 
OKT3-stimulated CD8 T cells 
RS = 0.777, 
p<0.001 
RS = 0.897, 
p<0.001 
RS = 0.116, 
ns 
RS = 0.952, 
p<0.001 
IE1-stimulated CD8 T cells 
RS = 0.893, 
p<0.001 
RS = 0.789, 
p<0.001 
RS = 0.143, 
ns 
RS = 0.761, 
p<0.001 
PPD-stimulated CD4 T cells 
RS = 0.948, 
p<0.001 
RS = 0.815, 
p<0.001 
RS = 0.285,  
p=0.02 
RS = 0.962, 
p<0.001 
Table 12: Correlations of amount of indicated activation marker per cell and number of displayed 
activation markers. Shown are Spearman’s correlation coefficient RS and p-value. 
 
Similar to pp65-specific CD4 T cells, pp65-specific CD8 T cells that produced several activation 
markers had increased MFIs for IFNγ, TNF and CD40L per cell (Figure 45). Although CD8 T 
cells producing all four activation markers, including CD40L were very rare, these cells 
contained the highest amounts of IFNγ, TNF and CD40L. The MFI for IFNγ, TNF and CD40L 
increased from T cells producing just one activation marker to all four. CD8 T cells producing 
IL2 had the highest MFI for IL2 when producing only 2 cytokines. In CD8 T cells all three 
combinations of cells producing IL2 and CD40L or IL2 and IFNγ or IL2 and TNF were observed 
(data not shown). All three subsets formed less than 5% of all responding CD8 T cells in all 
donors. The difference in the MFI between pp65-specific CD8 T cells producing only one to all 
four cytokines was very similar to the differences in CD4 T cells. Again, this was significant for 
all activation markers. The largest difference was seen for TNF (11-fold increase, p<0.001), 
followed by IFNγ (5-fold increase, p<0.001), CD40L (4-fold increase, p<0.001) and the smallest 
difference in the MFI was seen for IL2 (less than 2-fold increase, p<0.001).  
The same pattern of activation markers was observed in CD8 T cells stimulated with either IE1 
or OKT3 (Table 12, supplemental Figure 69 and Figure 70). 
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These data suggest that polyfunctional CD4 T cells were, independent of the used stimulation, 
more efficient than monofunctional cells because they produced several effector molecules in 
parallel and synthesised more of each cytokine on a per cell level [124-129]. At the same time, 
the downregulation of the surface markers CD3, CD4 and CD8 were stronger on polyfunctional 
cells than on monofunctional cells indicating a stronger activation.  
6.5 Effect of CMV infection on unrelated T cell responses  
It is generally accepted that CMV infection alters the immune system in many different ways. To 
investigate if CMV infection had an effect on polyclonally stimulated T cells, PBMC from 
CMV-seropositive (n=24) and CMV-seronegative donors (n=25) were stimulated with OKT3 
and analysed.  
There were only minor differences in the response size of the CD4 T cell compartment after 
OKT3 stimulation in CMV-seronegative and CMV-seropositive donors. However, the 
distribution of memory subsets was significantly altered (Figure 47). Donors with CMV 
infection had proportionally more responding CD4 TEM and TEMRA cells (p<0.001 and p=0.001 
respectively) compared to CMV-negative donors, while TCM cells were reduced (p=0.048). In 
terms of absolute numbers, CMV infected donors had significantly more responding CD4 TEM 
and TEMRA cells (supplemental Figure 74, p<0.001 for both). Polyclonally activated CD4 T cells 
from CMV-positive donors contained proportionally more polyfunctional and less 
monofunctional T cells than CD4 T cells from CMV-negative donors (Figure 47, p=0.005). 
Activated CD4 T cells from CMV-infected and uninfected donors produced the same quantities 
of cytokine per cell (data not shown). 









 Results  84 
CMV-infection altered the memory subset distribution in the entire T cell compartment and these 
changes were correlated with the size of the pp65-specific T cell response. Large pp65-specific 
responses were associated with marked losses and gains in TN and TEM cell compartments, 
respectively, small responses were associated with negligible changes. 
The frequency of responding T cells to stimulation with CMV peptide pools pp65 and IE1 or the 
polyclonal stimulus, OKT3, increased with age of the donor. Polyfunctionality was increased in 
large CMV-specific T cell responses. 
Polyfunctional T cells expressed quantitatively and qualitatively more activation marker on a per 
cell level than monofunctional cells and showed increased TCR and co-receptor downregulation 
upon activation.  
In addition, CMV infection appeared to affect unrelated immune responses. CMV-infected 
donors displayed higher numbers of activated T cells of a more advanced differentiation 
phenotype following polyclonal or PPD-specific stimulation.  
Polyfunctional pp65-specific T cell responses were inhibited by in vitro incubation with 
immunosuppressive drugs whereas degranulation of T cells was not affected. 
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7 Discussion 
7.1 T cells 
To gain more insight on the complex interaction of CMV infection and the human immune 
system, CMV-induced alterations in the T cell compartment of individuals in different age 
groups were analysed. PBMC from 50 donors were stimulated in vitro with a range of antigens 
and mitogen (pp65, IE1, PPD and OKT3) and the phenotype markers CD45RA and CD27 as 
well as the effector functions CD40L, IFNγ, IL2 and TNF were examined by multicolour flow 
cytometry. 
CD4 and CD8 T cells (defined by the lineage markers CD3, CD4 and CD8) were analysed to 
investigate whether changes occurred as a consequence of age. Absolute counts and 
frequencies of CD3, CD4 and CD8 T cells and CD4/CD8 T cell ratios did not differ 
significantly between the three age groups. This is in accordance with other published results 
that showed no significant age-related differences of lymphocyte populations in healthy adults 
[107, 130-132]. However, most published data are inconsistent, showing either a decrease or 
no differences for absolute numbers and frequencies of CD3 T cells and absolute numbers of 
CD4 T cells with age [94, 117, 133-143]. The data also show an increase or no difference for 
frequencies of CD4 T cells and a decrease, an increase or no changes for the absolute counts 
and frequencies of CD8 T cells with age [94, 117, 133-143]. Most of these studies included 
more than 100 adult donors ranging from 18 -70 years. Only two studies included children, 
which alters the results since it is known that children have in, absolute terms, more CD4 and 
CD8 T cells, but less CD4 T and CD8 T cells in percent of all T cells than adults [94, 138]. 
Another reason for the discrepancies between the different studies might be the method. Some 
studies looked for correlations, others compared age groups with arbitrary cut-offs. Other 
methodological features, ethnic background, health status, environmental and genetic factors 
could also affect the results and account for the differences since the studies were conducted in 
different populations. 
As described previously, absolute counts for CD3, CD4 and CD8 T cells were higher in CMV-
seropositive than CMV-seronegative donors but only the differences for absolute CD3 and 
CD8 T cell counts reached statistical significance in this study [106-108, 144, 145]. This 
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resulted in a decreased CD4/CD8 ratio in CMV-infected donors as already published [106, 
107, 109]. Of note, only one (young) donor in this study had a CD4/8 ratio smaller than 1.  
In agreement with published reports, the frequencies of T cells and the absolute numbers per 
ml blood were highly correlated for all tested populations [146]. It is unclear, which parameter 
is more useful. For example, one donor may have very low T cell counts while another has 
very high T cell counts. The proportions of CD4 and CD8 T cells within this population may 
be identical. Hopefully, future studies will reveal which parameter is more closely related to 
disease outcome.  
7.2 Memory T cell subsets 
As they encounter their cognate antigen for the first time, CD4 and CD8 TN cells are activated 
and start undergoing antigen-dependent differentiation. Analysis of the expression of T cell 
surface markers such as CD45RA, CD45RO, CD27, CD28 and CCR7 has led to several 
models describing this differentiation pathway [147, 148]. For example, Hamann et al. (1997) 
based their model on the expression of CD45RA and CD27 to distinguish between TN, TCM, 
TEM and TEMRA cells [14]. 
In this study the same markers were used to distinguish between the four memory T cell 
subsets. TN cells express CD45RA, a surface glycoprotein which is involved in T cell 
signalling and CD27, a member of the TNF receptor family [149]. CD45 isoform expression 
(CD45RA or RO) is altered on T cells during and subsequent to activation. Whereas CD45RA 
is found on TN cells, CD45R0 is found on memory T cells [150]. Eventually, the most 
advanced memory T cells re-express CD45RA, which is why they are referred to as ‘revertant’ 
[151]. Although CD27 is not classified as a costimulatory molecule, it enhances responses by 
increasing T cell proliferation [16, 152, 153]. CD27 expression increases transiently with 
activation and is subsequently irreversibly downregulated on memory T cells after several 
rounds of cell division [154]. 
CD28, a costimulatory molecule, is another commonly used differentiation marker, [106, 112, 
155, 156]. Appay et al. (2002) provided a differentiation model based on the expression of 
CD27 and CD28, which distinguished between early, intermediate and late differentiated T 
cells [157]. During normal antigenic exposure, CD28 expression is reduced but is rapidly 
restored to the same level as before stimulation. The loss of CD28 on T cells is attributed to 
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repeated antigenic stimulation. CD8 T cells lose CD28 first and then CD27 whereas CD4 T 
cells lose CD27 first and then CD28 [59, 158]. Virtually no CD8 T cells express CD28 without 
CD27 while CD4 T cells do not express CD27 without CD28. Therefore, all CD27- CD8 T 
cells in this study can be assumed to be CD28- T cells. CD28- CD8 T cells in humans contain 
high frequencies of virus-specific functional memory T cells [159]. These T cells show 
enhanced cytotoxicity but impaired antigen-induced proliferation. In humans, all CD8 T cells 
express CD28 at birth but these cells decrease by half at the age of 80 years [160]. The 
resulting  increase of peripheral CD28- CD8 T cells with age is observed in primates and 
humans but not in mice [161]. The differences between human and murine immune systems 
and varying life spans are just two reasons why mouse models are of limited use in the study of 
immunosenescence. Furthermore, inbred mouse strains with single infections are not 
comparable to genetically diverse humans which undergo multiple infections during their 
lifetime. For these reasons, data generated on mice were only referred to if no data on humans 
were available.   
Unfortunately, it is difficult to compare data regarding memory T cell subsets from different 
published studies since different markers which identify only partly overlapping 
subpopulations were frequently used [94, 114, 117, 136, 138, 149, 162, 163]. The phenotypic 
markers CD45RA and CD27 were used in this study to distinguish between TN 
(CD45RA+/CD27+) and the three memory subsets: TCM (CD45RA
-/CD27+), TEM (CD45RA
-
/CD27-), and TEMRA (CD45RA
+/CD27-) cells [14]. It was shown that the simultaneous analysis 
of the four memory markers CD45RA, CD27, CD28 and CCR7 characterised more than 10 
different T cell populations and each additional phenotypic marker further increased the 
number of distinct T cell populations [162, 163]. For example, using multicolour flow 
cytometry to analyse 11 phenotypic markers resulted in 75 detectable T cell populations [149]. 
This multiplicity of memory T cell subsets suggests that the plasticity of these populations is 
greater than previously thought and that the analysis of just two markers significantly 
simplifies the picture. Given that the number of fluorescence channels, even on the most 
advanced machines, is limited, a compromise in the choice of markers has to be made. 
Independent of which differentiation markers are used, it is generally accepted that TN cells 
decline and memory T cells increase with age, as confirmed by the results shown in this study 
[94, 95, 114, 117, 136, 138, 164-166]. CD4 and CD8 T cell subsets underwent the same 
phenotypic shifts during ageing, but the changes were more pronounced in CD8 T cells. The 
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accumulation of memory T cells in older people can be explained by the reduced thymic 
output of TN cells, frequent activation of T cells and the fact that, TEM and TEMRA cells are more 
resistant to apoptosis than TCM and TN cells [167-171]. In addition, TCM and TN cells from old 
people were more sensitive to apoptosis than those from younger people, resulting in a further 
decrease of these T cell subsets in elderly people [168]. 
The four memory T cell subsets were further investigated with regards to TCR downregulation 
upon activation. The activation induced loss of CD3, CD4, and CD8 co-receptor expression 
was used as a surrogate marker for TCR downregulation.  The expression difference was 
determined by comparing the MFIs of CD3, CD4 and CD8 on the different memory subsets of 
unstimulated T cells. It was observed that CD3, CD4 and CD8 downregulation was more 
pronounced in more advanced memory subsets compared to TN cells. The same level of 
downregulation was seen across different age groups. It is known that successful activation of 
the T cell results in internalisation and degradation of TCR, CD3 and co-receptors [23, 172]. 
This TCR downregulation after activation is usually reversible to enable recurrent stimulation 
of T cells. The downregulation of TCR and co-receptors on T cells of advanced differentiation 
seen in this study indicates that subsequent T cell stimulation results in irreversible 
downregulation of TCR and co-receptors.  
CMV infection is known to alter the memory subset distribution of all T cells, irrespective of 
their specificity [107, 111-113, 119]. Memory T cells, which play an important role in viral 
control, are stimulated and proliferate each time CMV is reactivated. However, CMV is never 
eradicated by this response [92, 93]. In this study, the TEM and TEMRA cell subsets were 
proportionally bigger and the TN subset was proportionally smaller in CMV-infected people 
than in uninfected people. This was observed for CMV-specific T cells as well as the entire T 
cell population. These alterations were more pronounced in CD8 T cells than in CD4 T cells 
and more conspicuous in elderly people than in young people.  
The results of this study extend these observations by showing that this effect depends on the 
size of the pp65-specific T cell responses and not on the presence or absence of CMV infection 
per se. The bigger the pp65-specific T cell response was, the less TN and the more TEM cells 
were observed in the peripheral blood. It appeared that the pp65-specific response size was a 
better correlate for the overall memory T cell subset shift than the age of the donor, which is 
used in most studies. This is an important finding, suggesting that the way in which the 
immune system deals with pp65 determines whether the effect on the T cell compartment is 
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weak (small pp65-specific T cell response) or strong (large pp65-specific T cell response). Of 
note, the size of the IE1-specific CD8 T cell response was not correlated with an advanced 
memory distribution of the entire CD8 T cell compartment. It appears that the more abundant, 
structural pp65 protein has a stronger effect on shaping the immune system than the non-
structural IE-1 protein. It is still unclear, why large pp65 or IE1-specific T cell responses 
develop in some, but not other, individuals. Unfortunately it remains unclear whether large T 
cell responses to CMV invariably occur after many years of infection, or if some individuals 
simply never mount these large responses.  
In this study, the frequency of CD8 TEMRA cells was significantly correlated with age in both 
CMV-negative and CMV-positive individuals. Although TEMRA cells were thought to be 
associated with CMV infection, they have been found in other settings as well e.g. after yellow 
fever vaccine and in patients with tuberculosis [18, 173-175]. CMV-specific CD8 T cells are 
CD45RO during primary infection and some convert to CD45RA T cells later on [151]. 
CD45RA re-expression has been positively correlated with the time since clearance of the 
virus from blood after primary CMV infection in healthy people and with the duration of CMV 
replication in transplant patients [176, 177]. The frequency of TEMRA cells increased after 
primary infection in the first year and then reached an amount comparable to those found in 
long-term, latently infected individuals. It also has been demonstrated that high frequency of 
TEMRA cells seemed to be associated with control of HIV replication and a lower risk of 
intrauterine CMV transmission [176, 178]. TEMRA cells were initially described as highly 
cytotoxic terminally differentiated T cells with short telomers and therefore poor proliferative 
capacity [179-181]. Other publications showed that the telomeres were longer than in other 
memory subsets and that TEMRA cells proliferated upon antigenic stimulation [182-184]. The 
differentiation pathways and functions of this memory T cell subset have to be investigated 
further. 
Although there is no direct evidence that a highly differentiated T cell compartment has a 
negative impact on the immune response, individuals with a low frequency of TN cells are 
thought to be more susceptible to new infectious agents. The accumulation of highly 
differentiated CD8 T cells is one of the parameters included in the IRP, which predicted 
mortality in the elderly in a number of longitudinal studies [98, 99]. The IRP was defined by 
the Swedish longitudinal OCTO/NONA studies and also included poor proliferative T cell 
responses to mitogens, a CD4/CD8 T cell ratio of less than one and CMV-seropositivity. 
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Another study established that an inverse CD4/CD8 T cell ratio (i.e. <1) is associated with 
poor survival in elderly people [185]. Due to a significant positive correlation between the 
proportion of CD8 T cells and age, the CD4/CD8 ratio decreases in older people [139, 186]. 
Interestingly, it now appears that most immune parameters defining the IRP are influenced by 
CMV infection, but not by other persistent viral infections, e.g. EBV [187]. The mechanisms 
by which CMV infection might reduce survival in some elderly people are still unclear. 
Although 100% of people with an IRP were CMV-seropositive, 85% of the people without an 
IRP were CMV-positive as well [188]. This clearly points to an important role of host factors 
in determining the effect of CMV on the immune system. It would be interesting to analyse if 
the pp65-specific response size and therefore the CMV-driven shift in memory subsets is the 
same in elderly with or without an IRP. This may explain why only some people with CMV 
infection are in the IRP group. It seems that the manner in which the immune system of an 
individual handles the virus might be crucial rather than simply infection status. This 
explanation is supported by the results of this work, indicating that the way the immune system 
deals with the infection is more important than CMV infection itself. In agreement with this 
theory a recent publication suggests that individuals genetically enriched for longevity are less 
susceptible to CMV-associated age-driven immune alterations, which might reflect better 
immunological control of the virus and contribute to their decreased mortality rate [189].  
7.3 Polyfunctional T cell responses  
Studies of viral infections have highlighted the phenotypic and functional heterogeneity of 
antigen-specific T cells and recent studies suggested that T cells which express a multitude of 
effector functions simultaneously are more likely to be correlated with protective immunity 
than single cytokine producers [124-128, 190, 191]. In this study, a multicolour flow 
cytometric approach was used to identify phenotype and functional profiles of CMV-specific T 
cells. The expression of the activation markers IFNγ, IL2, TNF and CD40L in addition to the 
phenotype markers CD45RA and CD27 on CD4 and CD8 T cells in terms of proportions of T 
cells and absolute cell counts per ml blood were analysed.  
Several tools are currently available for the detection of specific T cells by flow cytometry 
(rev. in [29, 192, 193]). Methods include intracellular cytokine staining (ICS), MHC class I 
tetramers and dextramers, measurement of proliferation by CFSE or PKH dyes, 
phosphorylation and degranulation assays [33-39]. Several of these methods can be combined 
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to gain insight into antigen-specific immune responses and the methods have sufficient 
sensitivity to measure rare cell populations. This is important since antigen-specific T cell 
responses are usually very small. The measurement of intracellular cytokines in PBMC after 
stimulation was first done by Waldrop et al. (1997) to analyse CD4 T cell responses to CMV-
lysate [40]. The most commonly used parameter to investigate functional CMV-specific T cell 
responses is the frequency of either CD4 or CD8 T cells producing IFNγ after short-term 
stimulation [118, 146, 194-204]. Although IFNγ plays an important role in the control of 
infections, the frequency of IFNγ-producing T cells does not necessarily appear to be a good 
correlate of protection on its own [124, 205]. Recent studies suggest a critical role of 
qualitative differences in the T cell response for the prediction of disease outcome, assigning a 
protective role to subsets that are able to produce several cytokines simultaneously [124-129, 
190, 191, 206]. Therefore, four activation markers (INFγ, TNF, IL2 and CD40L) were 
analysed in this study. TNF is an important cytokine for fighting infections by mediating 
killing of intracellular pathogens [1]. IL2 promotes proliferation of effector T cells, whereas 
the expression of CD40L identifies mainly activated CD4 T cells that can activate dendritic 
cells [1, 30, 31]. T cells producing CD40L, IFNγ, IL2 or TNF in any combination after antigen 
stimulation are referred to as antigen-specific T cells. T cells expressing only one of the four 
activation markers were considered monofunctional T cells and T cells expressing more than 
one of the analysed activation markers were considered polyfunctional for the purpose of this 
study.  
Unfortunately, even with high-end flow cytometers, technical limitations are quickly reached 
when it comes to the analysis of complex T cell responses. For example, this study used an 
instrument able to detect 11 fluorescence colours, but difficult choices still had to be made. An 
11-colour staining panel including one ‘dump channel’ (to exclude specific unwanted cell 
populations), a viability dye, three T cell lineage markers (CD3, CD4 and CD8) and two 
phenotypic markers (CD45RA and CD27) allowed analysis of four activation markers. A 
dump channel, viability dye and lineage markers were considered essential, and at least two 
memory markers are required for achieving a reasonable distribution of T cell memory subsets. 
The use of four carefully chosen activation markers is likely to have identified the majority of 
polyfunctional T cells but may have missed some polyfunctional subsets altogether or 
‘misidentified’ them as monofunctional. This will have included cells upregulating markers 
other than those measured here. New T cell activation markers are continually identified that 
may have important roles in different infections. So far, mainly IFNγ has been used to identify 
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functional CMV-specific T cells but recent publications propose that chemokines like MIP-1α 
and MIP-1β might be expressed on more T cells and might therefore be better markers, 
especially for terminally differentiated T cells [207-209]. Another important feature in the 
antiviral immune response is degranulation of T cells which can be detected by CD107, 
however, for the technical limitations described above it was not included in the panel [210].  
Conclusions of this study are in agreement with other publications showing that the CD8 T cell 
response to viral proteins is larger than the CD4 T cell response (rev. in [120]). This may be 
because proliferative capacity is higher in CD8 T cells or because antigen presentation is more 
efficient for CD8 T cells than for CD4 T cells (rev. in [120]). In this study there was no 
significant correlation between the pp65-specific CD4 and CD8 T cell response, in contrast to 
other studies where a positive or negative correlation was found [211, 212]. 
Some of the discrepancies between reports might be related to the small numbers of donors per 
study and to methodical differences, such as addition of growth factors co-stimulation and the 
source of T cells e.g. fresh or frozen cells, PBMC or sorted cells. Although a variety of 
techniques like intracellular flow cytometry, MHC tetramers and ELISPOT enable the 
investigation of CMV-specific immunity, it is still not possible to enumerate all CMV-specific 
T cells. Stimuli such as peptide pools or tetramers identify just fractions of all CMV-specific T 
cells. Even the use of whole CMV-lysate will not identify all CMV-specific T cells, since CD8 
T cells are not efficiently stimulated [213]. Stimulation with CMV-lysate and peptide pools 
also requires a functional read-out and this limits the detection to only functional T cells. The 
use of tetramers also identifies dysfunctional cells but is epitope and HLA-restricted and might 
not work for all antigens [214]. Another important consideration is, that these studies only 
analyse T cells in the peripheral blood and T cells responsible for controlling or eradicating 
viruses might be in other tissues, e.g. bone marrow or lymph nodes [215-218]. During this 
study it became evident that the use of different fluorochrome-Ab conjugates also affect results 
in the same donor. The use of the same reagents and regular performance checks of the 
cytometer throughout the whole study allowed for direct comparisons between donors within 
this study but comparisons with the results of other studies may be limited for the above 
mentioned reasons.  
The results of this study showed an increase of the frequencies and absolute numbers of pp65-
specific CD4 and CD8 T cell response size with ageing, but this was not statistically 
significant for all correlations. As previously demonstrated frequencies of both CMV-specific 
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CD4 and CD8 T cells showed a wide range among CMV-seropositive individuals in this study 
[52, 118, 201, 219, 220]. Large responses also occur in young and middle aged people and it is 
likely that the duration of CMV infection in combination with other host factors (rather than 
simply age) determines response size in an individual. No correlations with age were found for 
IE1-specific CD4 or CD8 T cell responses. As previously observed, IE1-specific CD4 T cell 
responses in this study were very small in most donors and therefore excluded from further 
analysis [52, 56, 204]. The increase in response size might not correlate in a linear fashion with 
time since infection, but is likely to be a better correlate of it than age which is used in most 
studies. Only one study in a Sicilian population showed no increase in CMV-specific tetramer-
positive T cells with age [221]. In contrast, most cross-sectional studies showed that the CD4 
and CD8 T cells specific for pp65, IE1 and CMV-lysate increased in CMV-seropositive donors 
with advancing age [118, 119, 144, 212, 222-225]. Although it was shown that old people have 
increased frequencies of CMV-specific T cells it is still unclear, when this T cell expansion 
happens. For obvious reasons, so far no longitudinal study in healthy humans has been 
conducted to follow the time course of infection for more than one year. The investigation of 
primary CMV infection in healthy adults is very difficult because the time point of infection is 
usually unknown. Although CMV infection is mainly acquired during infancy and 
adolescence, the rate of CMV seroconversion in adults is still ~1% per year [48]. Therefore it 
is generally not possible to determine the length of time that individuals have been infected for. 
Studies in transplant patients and pregnant women with primary CMV infection showed that 
after an initial peak of CMV-specific T cells during primary CMV infection, the frequencies of 
CMV-specific T cells remained stable, at least for one year [108, 176, 198, 201, 220, 226, 
227]. One study monitored the responses to staphylococcal enterotoxin B (SEB) and CMV 
antigens for 6 month in healthy CMV-seropositive donors [93]. While the response to SEB 
was relative stable over time, the T cell responses to CMV-lysate and pp65 showed significant 
variability [93]. Although the response size varied, there was no trend towards an increase with 
time. This seems to be in conflict with studies showing an accumulation of CMV-specific T 
cells with advancing age. One explanation could be that the expansion happens constantly but 
on such a low level, that no differences can be detected in the time course of one year (if it 
were 5% of the response size per year, it would not be measurable after one year, i.e. 1% 
versus 1.05%, but after 10 years it would be 1,6%, i.e. a 60% increase). Another possibility 
might be that the expansion happens infrequently, especially at older age after reactivation of 
CMV [228]. It is also possible that the CMV-specific T cell response size increases 
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infrequently in individuals after exposure to exogenous CMV. For example, HIV-specific T 
cell responses in HIV-infected individuals increased with frequent exposure to exogenous HIV 
[229]. It has to be investigated, why some people display large CMV-specific T cell responses 
while others only maintain small T cell responses which seem to be sufficient to control CMV. 
Although it is generally accepted that CMV-specific T cells increase with age, it is still 
uncertain if the majority of these T cells are functional or not in older people. Few studies 
reported an accumulation of functional CMV-specific T cells in the elderly, but several studies 
suggested a loss of functional CMV-specific T cells in elderly people [99, 109, 118, 119, 144, 
212, 222-225]. These T cells, in particular CD8 T cells, have sometimes been described as 
dysfunctional T cells that supersede functionally more diverse T cells so that the immune 
system becomes less able to respond to challenges requiring T cell responses. Because 
functional readouts were used to detect and enumerate CMV-specific T cells in this study, it 
was not possible to analyse non-functional CMV-specific T cells. The results showed that the 
absolute numbers and frequencies of functional T cells after in vitro stimulation with pp65 and 
IE1 increased with advancing age. In addition, polyfunctional CD4 and CD8 T cells were 
increased in large pp65-specific responses. Irrespectively of response size or age a robust 
population of polyfunctional CMV-specific T cells was present and may be in control of CMV. 
The inference that in individuals with large CMV responses, T cells are dysfunctional, and, as 
a result, more of them are required to control CMV is not supported. 
All four analysed activation markers, IFNγ, IL2, CD40L or TNF in the T cell compartment 
were increased after pp65 stimulation with advanced age and every single marker was 
significantly correlated with the response size. In contrast to other studies, this study also 
observed an increase in IL2 producing T cells with age [208, 225, 230, 231]. Nevertheless, 
IL2-producing T cells accumulated less than cells expressing any of the other markers. Highly 
differentiated T cells lose the ability to produce IL2 as a consequence of the loss of the 
costimulatory receptor CD28 [14, 232]. The majority of CMV-specific T cells are highly 
differentiated and do not express CD28 [226, 233, 234]. This observation explains why fewer 
CMV-specific T cells express IL2 than other cytokines examined. In conclusion, this study 
does not confirm a loss of fully functional T cells with increasing response size or age if either 
all CD4 T cells or all CD8 T cells are used as the reference subset. The same observation was 
also seen if absolute counts in cells per ml blood were used. It cannot be ruled out that non-
functional T cells (not detected in this study for reasons discussed above) increase at a higher 
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rate than the polyfunctional T cells, but it can be excluded that non-functional T cells replace 
polyfunctional T cells.  
Since multicolour flow cytometry is a relative new technique and there is a multitude of 
possible markers, the analysis of data has not been standardised (and maybe never will be). 
Some efforts are being made to streamline reporting of experiments to make differences 
transparent [235]. It is important to note that the reference population in terms of defining an 
increase or decrease makes a significant difference. The use of the CD4 or CD8 population, or 
even absolute counts per ml blood as a reference measure the increase or decrease of certain 
specific subsets of a response, irrespective of other independent subsets which are part of that 
response. Several studies report a relative loss of functional CMV-specific T cells in elderly 
CMV-positive donor [109, 118, 222, 223]. At the same time, these studies report higher 
numbers of CMV-specific T cells with advanced age. Taken together, most of these published 
data could actually be interpreted to show a total increase of functional CMV-specific T cells 
with age which is in agreement with the results presented here [109, 118, 222, 223].  
Polyfunctionality was also analysed with respect to the four memory T cell subsets defined by 
CD45RA and CD27 expression. With pp65 and IE1 being immunodominant CMV-proteins, it 
was also of interest to analyse the T cell response to other stimuli, such as PPD and OKT3. 
Regardless of the stimulus, only small frequencies of TN cells were activated. The use of the 
two markers CD27 and CD45RA in this study did not define a pure TN cell population. The 
contamination with activated and/or differentiated T cells may have been as high as 13% 
[149]. For example, these T cells might be activated CD27+/CD28-/CD45RA+ T cells [163, 
184]. This explains why some of the T cells that were classified as TN cells in this study 
produced activation markers upon stimulation. A minimum of three differentiation markers is 
required to identify true TN cells which would not be expected to produce cytokines after short-
term stimulation with more than 95% accuracy [149]. Most activated T cells were observed in 
the TCM and TEM cell subsets for all used stimuli. CMV-specific CD4 and CD8 T cells and 
polyclonally stimulated CD4 T cells were mainly TEM cells. In comparison, PPD-specific CD4 
T cells and polyclonally stimulated CD8 T cells were primarily observed in the TCM cell 
subset. Supposing that polyclonal stimulation activates T cells of all specificities, the 
phenotype of these cells would present an average. CMV-specific T cells would be of a more 
advanced memory phenotype than the average, while PPD-specific T cells would be of a less 
advanced memory phenotype than the average. This is in accordance with other studies 
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showing that T cells specific for different pathogens display distinct phenotypes and effector 
functions [110, 157, 158, 162, 236-238].  
CD8 TEMRA cells were found to be activated after stimulation with pp65 and IE1. Previous 
research has found that CMV-specific CD8 T cells accumulate in the TEMRA cell subsets with 
average percentages as high as 50% of all CMV-specific T cells [176, 177, 215]. In this study, 
up to 70% CD8 TEMRA cells were seen, but the average for CD8 TEMRA cells was only ~14% of 
all pp65 and IE1-specific CD8 T cells. As observed for all responding T cells, there were large 
inter-individual variations regarding the memory T cell subset distribution of activated T cells.  
While TN cells were, for the most part, monofunctional regardless of the stimulus used, the 
polyfunctionality of the other three memory subsets was dependent on the stimulus. In general, 
antigen-specific stimulation with CMV-antigens and PPD resulted in a more polyfunctional T 
cell response than polyclonal stimulation with OKT3. Stimulation with pp65 induced high 
frequencies of polyfunctional T cells in all three memory T cell subsets (TCM, TEM and TEMRA), 
while less IE1 stimulated T cells were polyfunctional. PPD induced only polyfunctional T cells 
in the TCM and TEM subsets. More CD4 T cells than CD8 T cells produced three or four 
activation markers simultaneously because CD40L is mainly expressed on activated CD4 T 
cells. As mentioned above, the measurement of four activation markers cannot provide a 
complete picture of polyfunctional T cells. Nonetheless, these data suggest that the 
polyfunctionality of T cells is not only dependent on the differentiation of T cells but also on 
the stimulus. This is in agreement with the findings that polyfunctionality of T cells depends 
on different factors such as the type of antigen, APC, antigen concentration and antigen-
dependent differentiation stage of the T cell [125, 210, 230, 239-241]. In T cells with higher 
antigen-sensitivity antigen contact results in a stronger signal than in T cells with lower 
antigen-sensitivity, and a stronger signal then translates into a more polyfunctional profile 
[125].  
TCR downregulation directly follows T cell activation and the degree of TCR downregulation 
is known to correlate with antigen-sensitivity [42, 172, 241-243]. As a result, one would expect 
TCR downregulation to be directly linked to polyfunctionality and the results shown here 
confirm exactly this. Activation induced CD3 downregulation (as a surrogate for TCR 
downregulation) directly correlated with the number of upregulated activation markers. The 
CD3 and CD4 surface expression on CD4 T cells and the CD3 and CD8 surface expression on 
CD8 T cells were downregulated on the surface of activated CMV-specific T cells. The 
 Discussion  97 
downregulation of these surface molecules was more pronounced when the number of different 
cytokines produced per cell was higher.  
The results presented here show that T cells producing multiple cytokines simultaneously also 
express more cytokine per cell than the equivalent single producers, supporting the idea that 
they might be more efficient [21, 120, 124, 240]. This was observed for CD4 and CD8 T cells 
after stimulation with PPD, CMV peptides and OKT3, indicating that it is a general feature of 
T cells independent of the stimulation. The more activation markers a cell expressed, the 
higher the quantity of CD40L, IFNγ and TNF per single cell. The situation was different when 
the expression of IL2 was analysed. Although subsets expressing IL2 in combination with one 
other cytokine were very small, these T cells produced significantly more IL2 per cell than 
monofunctional T cells or T cells producing three or four activation markers. Moreover, the 
expression levels of IL2 were consistent, irrespective of the activation marker that was being 
co-expressed. It is unclear, why the pattern of IL2 expression in polyfunctional T cells is 
different from the expression patterns of TNF, IFNγ and CD40L. It appears that IL2 plays an 
important role in the early stages after antigen encounter, in particular with respect to 
proliferation, indicating that T cells at that stage do not need to be polyfunctional. Further 
studies investigating more activation markers may help to better understand expression 
patterns of polyfunctional T cells. 
In conclusion, this study does not confirm a loss of T cell functionality with increasing 
response size and/or age. The pp65-specific T cell responses clearly suggest that bigger 
responses include more polyfunctional T cells. The results indicate that response size rather 
than donor age might be a better indicator of the duration of CMV infection. It certainly 
appears to be more closely correlated to other observable changes within the T cell response 
(subset distribution and polyfunctionality) rather than donor age. Since the CMV-specific T 
cell response size increases over time after CMV infection, it is likely there will be a 
correlation with age. This study supports the notion that host factors regulating CMV-specific 
T cell response size have a crucial role in determining the extent to which CMV affects the 
cellular immune system in general.  
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7.4 Effect of CMV on unrelated T cell responses 
Infection with CMV emphasises the effects of ageing on the immune system and is known to 
impair the immune system in various ways. Nevertheless this work showed that CMV infected 
individuals had bigger T cell responses to antigen-specific (PPD) and polyclonal (OKT3) 
stimuli than uninfected individuals. PBMC from CMV-infected and uninfected donors were 
stimulated overnight with protein purified derivative (PPD) from Mycobacterium tuberculosis 
or OKT3 and subsequently analysed by flow cytometry. Expression of the phenotype markers 
CD45RA and CD27 and the effector molecules CD40L, IFNγ, IL2 and TNF were examined. 
PPD was used as a recall antigen to analyse CMV-unrelated antigen-specific T cell responses. 
Over 2 billion people are infected with M. tuberculosis and more than 85% of all children 
worldwide are vaccinated with Bacillus Calmette-Guérin (BCG), a vaccine against 
tuberculosis that is prepared from a strain of attenuated live Mycobacterium bovis [244, 245]. 
Therefore, most people show a specific CD4 T cell response to PPD and these T cells express 
IFNγ, IL2 and TNF [246, 247].  
CMV infected donors had higher absolute numbers of PPD-specific CD4 T cells per ml blood  
compared to uninfected donors but the frequency in terms of CD4 T cells was similar in both 
groups. No CD8 T cell response was detected after stimulation with PPD. The responding CD4 
T cells showed a similar cytokine pattern in CMV-infected and uninfected individuals whereas 
the memory T cell distribution changed. CMV-seropositive people had both proportionally and 
in absolute numbers more responding PPD-specific TEM cells after stimulation. This is 
consistent with previous studies showing that T cells specific for bacterial (PPD) and other 
viral (HSV, EBV) antigens are more differentiated in CMV-positive donors than in CMV-
negative donors [248]. If these cells are of advantage or disadvantage for the host has to be 
investigated.  
It is well known that CMV infection impairs the immune system, but only a few studies have 
been carried out that focus on the influence of CMV on co-resident infections in humans. In 
mice it is described that murine CMV protects mice from bacterial infection [249]. The authors 
suggest that enhanced levels of T cell activation and secretion of IFNγ due to the chronic 
presentation of viral antigens protects the host from subsequent bacterial infections. In humans 
during acute CMV infection, the absolute numbers of EBV specific CD8 T cells dropped 
temporarily and recovered [108]. This is in contrast to a study conducted by Khan et al. (2004) 
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that demonstrated that CMV infection impaired the response to a coresident EBV infection 
permanently [118]. CMV infection also impairs the response to influenza vaccine in elderly 
people [250]. It was recently published that the total number of CD8 T cells increases with 
immunological experience, e.g. vaccination but impairs pre-existing TEM cells [251, 252]. In 
this study, the PPD-specific cells are not impaired by CMV infection but in contrast the PPD-
specific T cell response is actually enhanced. About 60% of CMV-infected CD4 T cells in 
HIV-infected donors produce MIP-1α and MIP-1β and are therefore protected against HIV 
infection [118, 207]. Nonetheless, CMV infection seems to enhance the progression of AIDS 
and CMV viral load has a strong association with mortality in patients with late-stage AIDS 
[70, 253]. In contrast, recent studies show that CMV and EBV-specific T cells contribute to 
antiviral T cell responses in humans [254, 255]. In these studies the T cell response to primary 
viral infections such as hepatitis B, HIV and dengue virus consisted of up to 20% of EBV and 
CMV-specific activated T cells. It is not yet known which mechanisms underlie this unspecific 
activation. One possible explanation may be the occurrence of TCR sharing between different 
T cells [256]. The contribution to immune responses to heterologous viral infections indicates 
an advantage of CMV infection for the human host [254, 255]. The CMV-specific T cells that 
were activated by other viral infections were found after primary infection in vivo and it is 
unclear if such activation was due to virus-specific factors or inflammation in general and if 
this could also happen after in vitro short-term stimulation. In this study, CMV-infected donors 
had larger responses to stimulation with PPD in terms of absolute numbers and it is possible 
that some of these activated T cells were CMV-specific. Another explanation is the induction 
of an inflammatory environment by CMV which drives also proliferation and differentiation of 
T cells specific for other pathogens [248]. This would also explain why CMV-seropositive 
donors, in contrast to CMV-negative donors, have higher spontaneous cytokine production 
without antigenic stimulation, which was demonstrated in this work and in other previous 
studies [36, 93].  
CMV-infected people compared to uninfected people had also significantly more CD8 T cells 
both, in absolute numbers and proportionally, responding to polyclonal OKT3 stimulation. The 
number of responding CD4 T cells following OKT3 stimulation was not altered. Activated 
CD4 and CD8 T cell compartments contained significantly more TEM and TEMRA cells and 
appeared to be more polyfunctional in CMV-infected donors compared to uninfected donors. 
This is in line with published reports that demonstrated that more T cells from CMV-infected 
donors were activated in response to polyclonal stimuli (SEB, PHA) than T cells from 
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uninfected donors [106, 132, 145, 257, 258]. In other studies the frequencies of T cells 
responding to SEB and PMA/Ionomycin stimulation were similar in CMV-infected and 
uninfected people [95, 164, 222]. The influence of CMV infection on polyclonal T cell 
response remains controversial and needs further investigation.  
Due to the fact that most studies have analysed only pp65 and IE1-specific T cells it remained 
unclear whether the higher number of memory T cells in CMV-infected people was only due 
to an increase of CMV-specific memory T cells or if CMV was changing the entire immune 
response. This study suggests that the immune response to unrelated antigens was enhanced 
indicating that CMV alters the whole immune system by inducing an inflammatory 
environment. 
7.5 Effect of immunosuppressive drugs on CMV-specific T cell 
response 
CMV is still the major infectious complication after solid organ transplantation, affecting more 
than 50% of all patients and causing both direct and indirect morbidity [73-75]. Direct effects 
caused by the virus include nephritis, hepatitis, colitis and myocarditis. Indirect effects are 
caused by the interaction of the virus and host immune system and are associated with graft 
rejection, opportunistic infections and decreased recipient survival [72, 76].  
Solid organ transplant recipients have a high risk of CMV disease not only due to the 
immunosuppression but also because of immune system activation, triggered by the foreign 
organ. Immunosuppression itself does not reactivate the virus but prevents control of the 
activated virus by inhibiting the CMV-specific T cell response  [259]. CMV-reactivation can 
be triggered e.g. by stress, immune activation and some cAMP-elevating drugs [259]. The 
level of immunosuppression required depends on the transplanted organ since different 
transplant organs induce different levels of immune activation. In contrast to heart transplant 
patients or heart-lung-transplant patients, liver and kidney-transplant patients receive a lower 
dose of immunosuppression and can better control primary CMV infection [211]. Most liver 
transplant patients are treated with either CSA or FK506 to prevent rejection whereas heart, 
heart-lung, or lung recipients receive triple therapy (Calcineurin inhibitors, steroids and 
antiproliferative drugs) [260, 261].  
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In order to avoid unnecessary antiviral treatment of transplant patients with a low risk of 
CMV-disease, it is important to find immunological (e.g. specific T cell subsets) correlates of 
protection against CMV-disease. For this purpose it is important to understand how 
immunosuppressive drugs are affecting CMV-specific T cells. Different markers of immunity 
against CMV were proposed to be correlated with the clinical outcome of CMV infection. So 
far, no test is routinely used which can predict CMV disease. Viral load measured by PCR is 
not always associated with CMV disease [59, 262]. Sund et al. (2009) showed that the 
reduction of IFNγ-producing CD4 T cells during the first few months after transplantation 
correlated with the magnitude of the CMV DNAemia [200]. They proposed to use the relative 
reduction of T cell responses after transplantation since the absolute number varies hugely 
between individuals [200]. Other groups stated that the ratio of pp65-specific IFNγ-secreting 
CD8 T cells to tetramer-positive CD8 T cells is correlated with protection against CMV 
disease or that the time point of the first CD4 T cell response, and not the quantity of the CD4 
T cell response, is predictive for CMV disease [50, 199]. Additionally, plasma levels of 
cytokines and chemokines were investigated and high levels of IL8, as well as low levels of 
MIP-1α, were found to be associated with CMV disease [263]. The total leucocyte count 
decreased prior to an increase of CMV viral load in heart transplant patients with CMV disease 
[264]. To date, none of the aforementioned immunological markers has been generally 
accepted to predict the risk of CMV disease.  
To find out how immunosuppressive drugs affect CMV-specific T cell responses, PBMC from 
healthy CMV-seropositive donors were incubated in vitro with CSA and FK506 and 
subsequently stimulated with pp65.  Calcineurin inhibitors were selected for these experiments 
since most transplant patients receive them. The activation markers CD40L, IFNγ, IL2, TNF 
and CD107a were analysed by flow cytometry. The immunosuppressive drugs CSA and 
FK506 suppressed in vitro production of the cytokines IFNγ, IL2 and TNF, but not 
degranulation in pp65-specific CD8 T cells. Both the number of cytokine-producing T cells 
and the quantity of cytokine secreted per cell were reduced after short-term pre-incubation with 
CSA or FK506. The cytokine profiles of PBMC incubated with either CSA or FK506 were 
very similar since both immunsuppressive drugs interfere with the same pathway. CSA and 
FK506 both inhibit the dephosphorylation of the transcription nuclear factor of activated T 
cells and thereby inhibit the synthesis of IL2. At physiological concentrations (200 ng of CSA, 
10 ng of FK506) the polyfunctional T cell subsets were reduced to approximately the same 
levels as in transplant patients [265]. In this study the frequencies of CD8 T cells producing 
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IFNγ, IL2 or TNF as well as the MFIs of IFNγ and TNF were significantly reduced after pre-
incubation with immunosuppressive drugs. Engstrand et al. (2003), by contrast, reported that 
the secretion of IFNγ is not affected by in vitro incubation with CSA up to 400 ng/ml [199]. In 
addition, they showed that the MFI of IFNγ did not differ between healthy and 
immunosuppressed donors. However, Sester et al. (2005) showed a decrease in CMV-specific 
CD8 T cell reactivity at low doses while CD4 T cells were inhibited at higher dosages of CSA 
and FK506 [146]. Comparably, in the results reported here, the frequency of IFNγ-producing 
CD8 T cells was downregulated by 50% at concentrations as low as 40ng/ml. In contrast, 
others found that compared to healthy controls, transplant patients with physiological plasma 
levels of either CSA or FK506 showed impaired IL2 but not IFNγ-secretion [260]. 
Investigations with immunosuppressive reagents showed again how important it is to study 
appropriate markers. If the panel had excluded CD107a, a massive loss of reacting cells would 
have been seen. By including CD107a it was shown that the T cells were still responding, but 
the effector mechanisms changed from multiple effector functions to degranulation only. It is 
possible that these cells produced other effector molecules which were not investigated in this 
work.  
7.6 Outlook 
In this study the focus was on the response size rather than donor age, because this seems to be 
a better indicator of the duration of CMV infection. It certainly appears to be more closely 
correlated to other observable changes within the T cell response such as subset distribution 
and polyfunctionality rather than donor age. Since the CMV-specific T cell response size 
increases over time after CMV infection, for epidemiological reasons, there will be a 
correlation with age. The data shown here support the idea that the way the immune system 
responds to CMV by mounting a big or a small response, rather than the infection itself, makes 
a big change in terms of the effect CMV infection has on the immune system in general.  
Many more questions have to be answered, for example, how does CMV accelerate 
immunosenescence in some people? Why do some people generate large CMV-specific 
responses while others can control the virus with small numbers of specific T cells? How does 
CMV induce further differentiated T cells and what role do they play? Why are CD8 T cells 
more prone to phenotypic changes than CD4 T cells? What are the best biomarkers to measure 
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immunosenescence? What are the best activation markers to measure CMV-specific T cells? 
What signalling pathways determine if a T cells is monofunctional or polyfunctional? Do 
“dysfunctional” T cells exist? What are “protective” T cells? How does CMV alter T cell 
responses to other antigens?  
To help answer these questions, based on the results presented here, this study will be 
expanded, including more people, especially in the elderly group. To investigate the interaction 
between CMV and immunosenescence, the immune response to 19 CMV protein-spanning 
peptide pools will be examined in CMV-seropositive donors. Although pp65 and IE1 are 
among the major immunodominant proteins, the analysis of more additional proteins might 
reveal more accurate correlations with age. To get a better picture of the polyfunctional T cell 
response, the expression of CD107a as degranulation marker will be investigated as well. The 
memory T cell subsets in these donors will also be analysed to understand how CMV infection 
contributes to a further advanced memory subset distribution and immunosenescence in some 
people. These results will hopefully help to better understand the CMV-induced changes in the 
immune system. Ultimately this will contribute to finding ways of improving the immune 
response and therefore the quality of life in older people.  
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